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A B S T R A C T  
Mushrooms and their compounds are widely appreciated, not only for their nutritional 
but also for their medicinal properties. In fact, the search for various bioactive 
properties in different mushroom extracts or in the compounds isolated from those 
mushroom has been the focus of attention from the scientific community working in 
the area of natural products. The present work has focused on the study of the 
antitumor and immunomodulatory properties of extracts from three different 
mushrooms. Thus, the first aim of the present work was to gain insight into the 
mechanism of action of a methanolic extract of Cordyceps militaris in the non-small 
cell lung cancer cell line NCI-H460, since this extract had previously been shown to 
have tumour cell growth inhibitory activity in this cell line in particular. In addition, the 
second aim was to study the immunomodulatory activity of the Suillus luteus 
polysachararidic (PLS) extract and of the Morchella esculenta phenolic extract, using 
the monocytic THP-1 cell line which differentiates into machrophages upon 
stimulation. 
The response of NCI-H460 cells to the methanolic extract of C. militaris was studied 
regarding its effect on cellular viability, proliferation, cell cycle profile, apoptosis and 
DNA damage. Results showed that treatment with the methanolic extract of C. 
militaris caused a decrease in NCI-H460 cellular proliferation, a cell cycle arrest at 
G0/G1 and an increase in apoptosis. Interestingly, treatment with the extract was 
shown to increase the cellular levels of p53 and p21. Moreover, this study also showed 
evidence of cellular DNA damage caused by this extract, since increased levels of P-
H2A.X and 53BP1 foci/cell were observed. Overall, this part of the work suggested that 
the methanolic extract of C. militaris affected NCI-H460 cellular viability through a 
mechanism which involved DNA damage and p53 activation.  
In addition, preliminary experiments were carried out to gain insight into the 
immunomodulatory potential of a PLS extract of S. luteus and of a phenolic extract of 
M. esculenta in THP-1 cells. Results showed that neither of the extracts presented 
cytotoxicity towards THP-1 cells or induced THP-1 monocytes differentiation into 
macrophages. Interestingly, the PLS extract of S. luteus caused a dose-dependent 
increase in the metabolic activity of THP-1 monocytes, probably due to increased 
proliferation. These preliminary results need be further confirmed and continued in 
future work. 
 Overall, the work carried out in this thesis further supports the potential of 
mushrooms extracts in the search for bioactive compounds. 
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R E S U M O 
Os cogumelos e seus compostos são muito apreciados, não só pelas suas propriedades 
nutricionais, mas também pelas medicinais. De facto, a procura de propriedades 
bioativas em diferentes extratos de cogumelos ou em compostos isolados desses 
cogumelos, tem sido um foco de interesse da comunidade científica que trabalha na 
área de produtos naturais. O presente trabalho visou o estudo de propriedades 
antitumorais e imunomoduladoras de extratos de três cogumelos diferentes. Assim 
sendo, como primeiro objetivo deste trabalho pretendeu-se analisar o mecanismo de 
ação de um extrato metanólico de Cordyceps militaris na linha celular NCI-H460 (de 
cancro do pulmão de não pequenas células), uma vez que tinha sido previamente 
demonstrado que este extrato inibe o crescimento celular, destas células em 
particular. Além deste, um segundo objetivo visou o estudo da atividade 
imunomoduladora de um extrato polisacarídico (PLS) de Suillus luteus e de um fenólico 
de Morchella esculenta, usando a linha celular monocítica THP-1 que se diferencia em 
macrófagos, após estimulação. 
Foi estudada a resposta das células NCI-H460 ao tratamento com o extrato metanólico 
de C. militaris relativamente ao efeito na viabilidade celular, proliferação, perfil do 
ciclo celular, apoptose e no dano no DNA. Os resultados demonstraram que o 
tratamento com o extrato metanólico de C. militaris nas células NCI-H460 diminuiu a 
proliferação celular, bloqueou o ciclo celular nas fases G0/G1 e induziu apoptose. De 
particular interesse foi o facto de este extrato causar um aumento dos níveis de p53 e 
p21. Para além disso, este estudo também mostrou ainda evidências de danos no DNA 
causados por este extrato, dada a observação de aumento quer nos níveis de P-H2A.X 
como no número de 53BP1 foci/célula. Em geral, esta parte do trabalho sugeriu que o 
extrato metanólico de C. militaris diminuiu a viabilidade celular das células NCI-H460 
por um mecanismo que envolve a ativação de danos no DNA e de p53. 
Neste trabalho, foram realizadas experiências preliminares para averiguar o potencial 
imunomodulador de um extrato PLS de S. luteus e de um extrato fenólico de M. 
esculenta em células THP-1.  
Os resultados demonstraram que nenhum dos extratos analisados apresentou 
citotoxicidade para células THP-1 ou induziu a diferenciação desta linha celular de 
monócitos em macrófagos. De particular interesse foi o facto de se verificar que o 
extrato PLS do S. luteus causou um aumento (dependente da dose) da atividade 
metabólica de monócitos THP-1, provavelmente devido ao aumento da proliferação 
celular. Estes resultados preliminares terão ainda de ser confirmados num trabalho 
futuro, assim como o potencial imunomodulador destes extratos. 
De um modo geral, o trabalho realizado nesta tese contribui para a descrição do 
potencial dos extratos de cogumelos na busca de compostos bioativos. 
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1. Mushrooms 
 
In 1992, Shu-Ting Chang and Philip G. Miles defined mushroom as “a macrofungus with 
a distinctive fruiting body, which can be found either below ground (hypogeous) or 
above ground (epigeous), large enough to be seen with the naked eye and to be picked 
by hand” (Guillamon et al. 2010). Today, the word “mushroom” usually refers to the 
fruiting body of the complete fungus which is produced by a mature mycelium (a 
vegetative part of fungus, that allows the feeding and growth of the mushroom 
(Cheung 2008)). The mushroom structure is represented in Figure 1. 
 
Figure 1 –Mushroom structure. 
A) Cap, protect the gills; B) Gill, spore-producing part; C) Ring, remnant of a membrane that covers the 
gills of the immature mushroom; D) Stem, supports the mushroom cap; E) Volva, remnant of a 
membrane that covers the immature mushroom; F) Hypha, draws water and organic matter for the 
mushroom development; G) Spores, microscopic reproductive bodies; H) Mycelium, tangle of hyphae. 
The fruiting body is composed of A, B, C, D, E and G. [Adapted from 
http://www.ikonet.com/en/visualdictionary/static/us/edible_mushrooms in 21 July 2014] 
 
Mushrooms belong to the kingdom Myceteae, being the majority included in the class 
“Basidiomycetes” and the others in the class “Ascomycetes” (Cheung 2008 et al. 2013). 
There are several mushrooms, presenting a variety of shapes and colors (Cheung 
2008). Although it is not known how many mushroom species exist exactly on earth, its 
number has been estimated to be around 140.000, from which only a few 
(approximately 10%) have already been described. Furthermore, from the mushroom 
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species that have been already described, only few of them have been thoroughly 
studied (Hawksworth 2001, Wasser 2002, Khatua et al. 2013, Soares et al. 2013).  
Although mushrooms are distributed worldwide, their production may be seasonal 
(Miles and Chang 1997). This may be due mainly to the fact that their fruiting bodies 
require the availability of more nutrients than the ones necessary for the production of 
asexual spores by microfungi (Cheung 2008).  
Mushrooms may be divided in the four following categories, being  included in one or 
more of them: i) edible, which includes all mushrooms which may be ingested without 
harm ( Table 1); ii) medicinal, which are considered to have medicinal applications; iii) 
poisonous, which are suspected or proven to be poisonous and iv) “other 
mushrooms”, which includes a large amount of mushrooms whose properties remain 
unknown (Cheung 2008).  
 
Table 1 - Some edible mushrooms 
[Adapted from (Chang 2001)] 
Genera of prime edible 
mushrooms 
 
Species of commercially cultivated edible mushrooms 
Ascomycetes Species which have reached an industrial scale 
Morchella Tuber Agaricus bisporus Agaricus bitorquis 
Basidiomycetes Flammulina velutipes Lentinula edodes 
Agaricus Agrocybe Pleurotus ostreatus Volvariella volvacea 
Amanita Armillaria Others 
Auricularia Boletus Agaricus blazei Auricularia auricular 
Cantharellus Calvatia Auricularia fuscosuccinea Auricularia polytricha 
Clitocybe Coprinus Coprinus comatus Dictyophora duplicate 
Cortinarius Dictyophara Dictyophora indusiata Grifola frondosa 
Flammulina Gloestereum Hericium erinaceus Hypsizygus marmoreus 
Grifola Hericium Lyophyllum ulmarium Pholiota nameko 
Hypholoma Hypsizgus Pleurotus citrinopileatus Pleurotus cornucopiae 
Lactarius Lentinula Pleurotus cystidiosus Pleurotus djamor 
Lepista Lyophyllum Pleurotus eryngii Pleurotus florida 
Marasmius Pleurotus Pleurotus sajor-caju Stropharia rugoso-annulata 
Pholiota Polyporus Tremella aurantia Tremella fuciformis 
Russula Stropharia Volvariella diplasia Volvariella esculenta 
Termitomyces Tremella   
Tricholoma Volvariella   
 
 
This thesis focuses mainly on the study of edible mushrooms with medicinal 
properties, namely antitumor and immunomodulatory. 
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1.1. Edible mushrooms and their nutritional properties 
 
Edible mushrooms have been cultivated, consumed (both in fresh and processed 
forms, cooked or raw) and appreciated by many people around the world for 
thousands of years. In fact, mushrooms existed on earth even before man (as indicated 
by a fossil from the lower cretaceous period), raising the possibility that man have 
been using mushrooms as food since the most primitive times (Wani et al. 2010).  
From all the species of mushrooms described worldwide, approximately 2000 have 
been described as edible, although  (Lakhanpal and Rana 2005, Wani et al. 2010) only 
around 100 are experimentally grown, 50 are economically cultivated, approximately 
30 are commercially cultivated and only fewer than 25 species are accepted as food 
(Chang 2001). In most countries, probably due to their unique flavour and texture, the 
consumption of cultivated mushrooms is well-established (Lindequist et al. 2005, 
Wong and Chye 2009, Kalyoncu et al. 2010, Wani et al. 2010, Ren et al. 2012, Tibuhwa 
2012). Nevertheless, a specific group of edible mushroom species called 
“ectomycorrhizal” (that create symbiotic relations with their host plants) (Yun and Hall 
2004) are only consumed seasonally, by local people (from the areas where those 
mushrooms grow), enthusiasts and gourmets (Chang 2001, Kalmiş et al. 2011). From 
all the species of mushrooms considered as food, the most popular, and usually mostly 
consumed around the world, are the Agaricus bisporus (also known as “button 
mushroom”) and Lentinus edodes, (also known as “shiitake”) (Mattila et al. 2000).  
The majority of mushrooms are similar in terms of basic constitution:  90% water and 
10% dry matter (Wani et al. 2010). From the nutritional point of view, mushrooms 
comprise a valuable source of healthy food, which is low in calories/energy (having 
only approximately 150 kJ per 100 g of fresh mushroom) (Cheung 2008, Kalač 2009, 
Khatua et al. 2013). Their nutritional value is due to their significant content in: 
antioxidant compounds, fibers, proteins (and enzymes), essential amino acids 
(containing all the nine essential amino acids for humans), carbohydrates (such as 
chitin, glycogen, mannitol and trehalose), lipids, minerals, vitamins and water, which 
can be efficient health promoters (Mattila et al. 2001, Lakhanpal and Rana 2005, 
Cheung 2008, Kalač 2009, Guillamon et al. 2010, Kalyoncu et al. 2010, Rathee et al. 
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2012, Tibuhwa 2012, Soares et al. 2013). In addition, it is also important to refer that 
they have a high content of digestible carbohydrates (approximately 50 to 60%) and 
that their protein content (between 27 to 48%) is equivalent to muscle protein (Khatun 
et al. 2012) and is higher when compared to most vegetables (Chang 2001, Lakhanpal 
and Rana 2005, Kim et al. 2008, Wani et al. 2010).  
 
1.2. Pharmacological properties of edible mushrooms  
 
Mushrooms are not only a source of nutritional properties but some of them also 
possess medicinal value (Sharma and Atri 2014).  
Medicine and natural products have been, for a long time, intimately correlated 
through the use of traditional medicines and natural poisons (Ferreira et al. 2010). 
Food is no longer seen, and ingested, only as a source of required nutrients and to 
satisfy hunger, but also to prevent diseases and improve physical and mental well-
being (Menrad 2003).  
Interestingly, the great majority of the commercialized drugs has been produced from 
secondary metabolites of natural products or their chemically synthesized analogs (Li 
and Vederas 2009). Examples of such drugs which are used in the clinic are: i) 
penicillin, an antibiotic derived from Penicillium; ii) cyclosporine, an 
immunosuppressant derived from Tolypocladium inflatum, and iii)  taxol, camptothecin 
and doxorubicin, anticancer drugs derived from Taxus brevifolia, Cuscuta reflexa and 
Streptomyces peucetius, respectively (Li and Vederas 2009, Kumar et al. 2013).  
Mushrooms fulfill the criteria suggested by Baker in 1995, to consider natural species 
as sources of compounds with potential medicinal properties (Baker et al. 1995). These 
criteria are: a) evidence regarding the traditional use of the substance by indigenous 
populations; b) abundance of the species in nature; and c) sustainable use of the 
species (Ferreira et al. 2010). 
Therefore, increased interest is being given to mushrooms (and their components), as 
a major untapped source of biologically active compounds with pharmacological 
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applicability which may be used in the development of potent new pharmaceutical 
products (Lakhanpal and Rana 2005, Rai et al. 2005, Cheung 2008, Ferreira et al. 2010, 
Kalmiş et al. 2011, Palacios et al. 2011, Khatun et al. 2012). Since mushrooms grow in 
darkness and dampness, in extremely competitive environments, they have the need 
to defend themselves from other microbes. This stimulates the accumulation of a 
diversity of secondary metabolites (such as phenolic compounds, terpenes and 
steroids) and of essential cell wall components (such as polysaccharides, β-glucans and 
proteins), several of them having important biological activities (Ferreira et al. 2010, 
Soares et al. 2013). Therefore, it is not surprising that mushrooms are capable of 
producing different important biologically active compounds which may be used in 
therapy, since they frequently need these natural protective substances for their 
survival (Ferreira et al. 2010, Soares et al. 2013). 
Although the interest in the pharmacological properties of mushrooms appears to be 
recent, mushrooms have been used for generations in Oriental medicine. (Lindequist 
et al. 2005). Ancient civilizations like Greeks, Egyptians, Romans and Mexicans valued 
the therapeutic nature of mushrooms. Also Vedas, the oldest religious scriptures of 
Hinduism, mentioned the medicinal value of mushrooms, whereas the Romans 
considered mushrooms the “Food of the Gods” and the Chinese defined mushrooms 
as the “Elixir of life” (Mattila et al. 2000, Chang 2001). Their application in the Western 
hemisphere of the globe has been growing slightly over the last decades (Lindequist et 
al. 2005, Zong et al. 2012, Khatua et al. 2013). Mushroom preparations are considered 
a tonic with beneficial health effects (Lakhanpal and Rana 2005, Rai et al. 2005, 
Ferreira et al. 2010) and their extracts have already been proved to be generally well-
tolerated with few, or any, side-effects (Roupas et al. 2012). In fact, many studies have 
suggested that the daily use of specific mushrooms (and/or their derivatives) in the 
diet may provide health benefits for the major functions of the human body, 
particularly since they presumably protect against oxidative damage, among other 
properties. They also have been described as prophylactic and healing promoters 
(Poucheret et al. 2006, Cheung 2010, Tibuhwa 2012). 
Since mushroom are not (yet) directly used as a pharmaceutical product, their use as 
complementary medicine/dietary supplements may give them the connotation of 
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“nutraceuticals” (a substance which may be a food (or part of it) and is also beneficial 
for health, both in the prevention and treatment of diseases (Chang 1996, Lakhanpal 
and Rana 2005, Cheung 2008, Khatun et al. 2012, Soares et al. 2013). 
From all the known species of mushrooms, approximately 1800 have been identified as 
having potential medicinal properties, and around 300 have recognized medicinal 
properties (Cheung 2008, Sharma and Atri 2014). For example, metabolites from 
Basidiomycetes were established as having pharmacological activity in several diseases 
such as: oxidation associated diseases, chronic inflammation, infections, diabetes, 
immune system disorders and cancer (Lakhanpal and Rana 2005, Poucheret et al. 
2006, Cheung 2008). Agaricus blazei, Cordyceps militaris, Ganoderma lucidum, Grifola 
frondosa, Hericium erinaceous, Lentinus edodes and Pleurotus ostreatus (Table 1) are 
just a few of the cultivated Basidiomycetes whose medicinal value has been studied 
(Wasser 2002, Lakhanpal and Rana 2005, Zaidman et al. 2005, Khatun et al. 2012). 
However, the nutraceutical and medicinal value of a large number of species remains 
unknown (Lakhanpal and Rana 2005). Thus, the study of those less studied mushrooms 
(and of their compounds) is of great interest due to the variety of biomolecules with 
medicinal properties (Poucheret et al. 2006) they may possess. 
Each mushroom has a particular composition (Palacios et al. 2011) that may have 
several applications. Some of the compounds which are found in mushrooms with 
biological activity include: polysaccharides, proteins, fats, ash, glycosides, alkaloids, 
volatile oils, tocopherols, phenolics, flavonoids, carotenoids, folates, ascorbic acid, 
enzymes, organic acids, dietary fibers, oligosaccharides, triterpenoids and mineral 
compounds. Polysaccharides are the best known and also considered the most potent 
mushroom-derived substances, being described as having antitumor and 
immunomodulating properties, among others (Mattila et al. 2000, Wasser 2002, 
Cheung et al. 2003, Borchers et al. 2004, Lakhanpal and Rana 2005, Zaidman et al. 
2005, Patel and Goyal 2012). 
Mushrooms have been described as having several properties such as: antioxidants 
(Tibuhwa 2012), antitumor (Lakhanpal and Rana 2005), antibacterial (Voravuthikunchai 
et al. 2010), antifungal (Wong et al. 2011), antiviral (Wang et al. 2007), antiparasitic 
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(Oluba et al. 2012), immunomodulatory (Sheu et al. 2007) anti-inflammatory (Qian et 
al. 2012), hepatoprotective (Soares et al. 2013). Mushroom extracts also have been 
proven as capable of reducing the blood pressure and cholesterol concentration, which 
are intimately related to some diseases such as hypercholesterolemia (Lakhanpal and 
Rana 2005). Mushrooms are also an excellent source of folic acid, preventing anemia 
(Khatun et al. 2012). Other effects such as cytostatic, immunosuppressive, 
antiatherogenic, hypoglycemic and antiallergic are also found in different mushrooms 
(Miles and Chang 1997, Lakhanpal and Rana 2005, Lindequist et al. 2005). 
Although the therapeutic potential of several mushrooms has been already shown, 
their exact mechanisms of action, as well as the exact health benefits still require 
intensive investigation (Rathee et al. 2012).  
Some specific pharmacological properties of mushrooms and of their isolated 
compounds will be further referred in the following subsections. 
 
1.2.1. Mushrooms as natural source of compounds with antitumor activity 
 
1.2.1.1 Cancer: general remarks 
 
Cancer is one of the most serious health problems worldwide. It is the principal cause 
of death in economically developed countries and the second cause of death in 
developing countries, affecting individuals from different sexes, ages and races (Jemal 
et al. 2011). In 2012, the International Agency for Research on Cancer (IARC) through 
GLOBOCAN 2012, estimated a number of 14.1 million of new cases and of 8.2 million 
deaths related to cancer (Ferlay et al. 2013). It is expected that these numbers will 
continue to increase, not only due to the aging and growth of the world population, 
but also because of the risk behaviors of our society, which may lead to the 
development of cancer (Jemal et al. 2011, Siegel et al. 2012).  
Data published in 2012 indicated that lung cancer was the most commonly diagnosed 
cancer worldwide (1.8 million cases, corresponding to 13.0% of the total number of 
cases) being also the most abundant cause of cancer-related death (1.6 million, 19.4% 
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of the total number of cases). In Europe, lung cancer was the second most commonly 
diagnosed type of cancer (15.9%; behind prostate cancer, which corresponded to 
22.8%) and was also the major cause of cancer related deaths in 2012 (26.1%) (Ferlay 
et al. 2013).  
Cancer is usually characterized by an abnormal and uncontrolled cellular growth 
(Kumar et al. 2012) which may be induced by several factors, all interacting with each 
other or in sequence. These factors may be: i) genetic alterations, which may be 
inherited or result from accumulated genetic mutations (leading to alterations in 
oncogenes, tumor-suppressor genes or microRNAs) ii) lifestyle or iii) environmental 
factors (Pharoah et al. 2004, Croce 2008). The abnormal and uncontrolled cellular 
growth may be reflected in changes in cell proliferation and/or cell death. In some 
cases, tumor cells acquire the ability to invade the surrounding tissue, to metastasize 
and invade different normal tissues and organs. In fact, these metastases are already 
described to be responsible for 90% of cancer-related deaths (Ruddon 2007, Zhong 
and Xiao 2009, Zong et al. 2012). 
In 2000, a total of six hallmarks of cancer have been defined by Hanahan and Weinberg 
as being biological characteristics, shared by all cancers, which are acquired during the 
initiation and progression of tumors (Hanahan and Weinberg 2000). These included: i) 
sustained proliferative signaling, ii) resistance to cell death, iii) stimulation of 
angiogenesis, iv) unlimited replication, v) activation of invasion and metastasis and vi) 
evasion of  growth suppressor signals. In 2011, this subject was revised by the same 
authors and the suggested number of cancer hallmarks increased to ten through the 
inclusion of: i) deregulation of cellular energetic, ii) genome instability and mutation, 
iii) tumor-promotion inflammation and finally iv) avoiding the immune destruction 
(Hanahan and Weinberg 2011) (Figure 2). 
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Figure 2- Hallmarks of cancer 
Representation of the acquired capabilities of tumor cells essential for tumor growth and progression 
[Adapted from (Hanahan and Weinberg 2011)] 
 
1.2.1.1.2. Cancer therapy 
 
The most common strategies to treat cancer are based on surgery, chemotherapy, 
radiotherapy and immunotherapy (Fialho and Chakrabarty 2010). Nevertheless, all of 
them still present disadvantages and/or side effects and, for the majority of the cases, 
cancer treatment relies in the use a more than one of these approaches. 
Surgery is considered the first-line therapy for solid tumors, which are accessible via 
surgical incision. However, due to the high rate of local recurrence in non-metastatic 
patients, there is usually the need to use adjuvant therapy, with chemotherapy being 
currently the most common (Tan et al. 2009). 
Chemotherapy was introduced into the clinic in the 1970s and mainly targets the 
growth ability of cancer cells and induces cell death (Johnstone et al. 2002).  
Indeed, as previously referred, the ability of cancer cells to resist and modify the 
mechanisms that influence cell growth and cell death are included in the hallmarks of 
cancer (Hunter et al. 2007).  
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Cell cycle consists of a sequence of events required for growth and cell division. As 
represented in Figure 3, it includes the interphase (the intermission between two 
mitosis phases), the mitosis (the process of nuclear division) and culminates in 
cytokinesis (cytoplasm division). The interphase consists in three different stages: i) G1 
phase, the first period of growth during which the cell prepares for DNA synthesis), ii) S 
phase, in which DNA replication occurs and iii) G2 phase, during which the cell 
prepares for mitosis. DNA packaging and chromosome segregation occurs in mitosis 
and this stage includes prophase, metaphase, anaphase and telophase. Cells in G0 or 
quiescent cells are cells that are not growing or proliferating (Murray and Hunt 1993, 
Vermeulen et al. 2003, Berridge 2012). 
 
Figure 3 – Cell cycle phases. 
G1- G1 phase; S- S phase (DNA replication); G2- G2 phase; M- M phase (divided in mitosis, a nuclear 
division, and cytokinesis, a cytoplasmic division). [Adapted from (Alberts et al. 2002)] 
 
Usually, cell cycle is regulated between phases, at different checkpoints (evolutionarily 
conserved surveillance mechanisms) which allow to control and avoid abnormal events 
(Hartwell and Weinert 1989, Rowinsky 2005). In addition, cellular division in normal 
cells is limited in terms of number of successive cell cycles (Blasco 2007, Hanahan and 
Weinberg 2011). However, cancer cells seem to become “masters of their own 
destinies”, being able to alter cell cycle and sustaining chronic proliferation (Hanahan 
and Weinberg 2000, Vermeulen et al. 2003, Blasco 2005, Hanahan and Weinberg 
2011). 
Cancer cells also usually resist to apoptotic cell death. This type of programmed cell 
death, contributes towards the maintenance of the homeostasis in living organisms 
(Wang et al. 2012). The cell has the ability to continuously check its integrity and once 
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this integrity is affected, a cascade of events is activated resulting in the cell self 
destruction (Darzynkiewicz et al. 1997, Khosravi-Far and Degli Esposti 2004) (Figure 4). 
 
 
Figure 4 - Apoptotic pathways  
[Adapted from (Wang et al. 2012)] 
Induction of apoptosis may occur via two major pathways: the “intrinsic” (or mitochondrial pathway) 
and the “extrinsic” (or death-receptor pathway) (Hanahan and Weinberg 2011, Wang et al. 2012). In the 
intrinsic pathway, initiation occurs through the permeabilization of the outer mitochondrial membrane. 
Bax or Bak (Bcl-2 family proteins) dimerization regulates the formation of pores in the outer 
mitochondrial membrane, leading to the release of pro-apoptotic factors into the cytoplasm (such as 
cytochrome c), which associates with APAF-1 and procaspase-9, forming the caspase-9 activating 
complex. Active Caspase-9 then cleaves and activates caspases - 3, -6 and -7, leading to the cleavage of 
other substrates resulting in cell death (Jin and El-Deiry 2005, Wang et al. 2012). In the extrinsic 
pathway, the activation of receptors [Fas receptor (FasR), tumor necrosis factor receptor 1 (TNFR1), 
death receptor 4/death receptor 5 (DR4/DR5) and death receptor 3 (DR3)] occurs through the binding of 
their specific death ligands. This recruits the death-inducing signaling complex (DISC) to the cytoplasmic 
domain of the death receptors. DISC complex contains an adapter protein, which recruits procaspase-8 
into the complex and, consequently, activates caspase-8 which then cleaves and activates caspase-3, 
leading to apoptosis (Jin and El-Deiry 2005, Wang et al. 2012).  
 
 
Therefore, both cell cycle and apoptotic pathways are potential therapeutic targets for 
cancer treatment. Indeed, some of the conventional chemotherapeutic drugs are 
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known to reduce cancer cell growth by inducing cell cycle arrest and/or by inducing 
apoptosis (Hunter et al. 2007, Gerlinger and Swanton 2010).  
Although conventional chemotherapeutic drugs are still the most frequent strategy in 
anticancer therapy, they exhibit many undesirable/adverse side-effects. In particular, 
since the majority of the chemotherapeutic drugs are not able to distinguish between 
normal and cancer cells, this result in the damage of normal growing cells. In addition, 
many chemotherapeutic agents activate apoptosis by inducing DNA damage, which 
may result in an increase the cellular mutation rate. This may, lead to the cancer drug 
resistance (Travis 2006, Hunter et al. 2007, Xu et al. 2013). 
The development of anticancer drugs has been focusing in targets which are 
characteristic of tumor cells, and preferentially which are not expressed in normal cells 
(Brissette et al. 2006). These targeted therapies are therefore directed towards specific 
molecular targets, which may block one or more hallmark capabilities. The specificity 
of action of the more modern targeted therapies is an added value to cancer therapy, 
giving rise to comparatively less off-target effects and resulting in fewer nonspecific 
toxicity when compared to conventional chemotherapy (Hanahan and Weinberg 
2011). However, several targeted therapies also result in relapses (Hanahan and 
Weinberg 2011). This may be explained by the fact that a targeted therapeutic agent 
can inhibit one signaling pathway, but is not able to completely shut off a hallmark 
capability. Furthermore, cancer cells might adapt by changing their dependence 
on a hallmark over another, and may also survive with residual function and adapt to 
the selective pressure imposed by the therapy applied, acquiring resistance and 
consequently causing a relapse in the cancer patient (Hanahan and Weinberg 2011). 
Since tumors are a highly heterogeneous and highly dynamic mass of cells, they are 
extremely hard to destroy (Hunter et al. 2007, Gerlinger and Swanton 2010). 
Moreover, cancer is a multi-step process and may involve many different pathways 
(involving different epigenetic and genetic alterations). Therefore, different 
approaches have been studied in the last years to overcome cancer. In particular, the 
combination of therapies (targeting multiple pathways/targets) may offer higher 
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efficacy in treatment compared to therapy aiming at only one target (Csermely et al. 
2005).  
Based on the fact that the existing cancer therapies are still not fully effective, some of 
them having proved side effects and may have long-term consequences, the  
identification of novel and non-toxic therapeutic strategies is of prime concern (Kimura 
2005, Eschenhagen et al. 2011, Kumar et al. 2013).  
1.2.1.2. Examples of mushrooms with antitumor activity 
 
Over the last decades, the potential use of mushrooms extracts in cancer therapy has 
emerged (Zaidman et al. 2005, Ferreira et al. 2010). Several studies, carried out in 
different human tumor cell lines, as well as in animal models, have shown that 
mushroom extracts may either be used individually (due to their antitumor 
properties), or as adjuvants, helping and supporting immune function in cancer 
patients, prolonging survival during treatment with conventional therapies (radio and 
chemotherapy) (Patel and Goyal 2012, Sharma and Atri 2014). About two hundred 
species of edible higher Basidiomycetes extracts have already been described as 
potential tumor cell growth inhibitors (Lindequist et al. 2005, Poucheret et al. 2006). 
Thus, the study of potential antitumor effects of mushrooms compounds and their 
mechanism of action are extremely important, since they may be a valuable source of 
potential antitumor drugs. 
The first mushroom extract to be described as having antitumor properties was from 
Boletus edulis, in a study in which extracts of its fruiting bodies were tested against the 
Sarcoma 180 line in mice (Byerrum et al. 1957). Since then, several studies have 
described a vast number of compounds extracted from mushrooms with potential 
antitumor activity, acting through different mechanisms of action (Table 2). 
Compounds extracted from mushrooms which have potential antitumor activity may  
be divided in: i) low-molecular-weight compounds (LMW) such as quinones, 
cerebrosides, isoflavones, catechols, amines, triacylglycerols, sesquiterpenes, steroids, 
organic germanium and selenium and ii) high-molecular-weight compounds (HMW) 
such as homoglucans and heteroglucans, glycans, glycoproteins, glycopeptides, 
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proteoglycans, proteins and RNA-protein complexes (Ferreira et al. 2010). 
Polysaccharides can be extracted from different parts of mushrooms, like the 
mycelium and the fruiting body (Zhang et al. 2007). Glucans (HMW compounds) are 
considered the most important polysaccharides with antitumor potential (Ferreira et 
al. 2010, Ren et al. 2012). Nevertheless, the antitumor potential of mushroom 
polysaccharides does not seem to be a direct effect on the tumor but to be largely 
associated to their ability to modulate immune response (both innate and adaptive) 
(Borchers et al. 2004, Zaidman et al. 2005, Roupas et al. 2012). 
 
Table 2 - Some examples of extracts from mushrooms which have shown antitumor activity 
Adapted from (Popovic et al. 2013). 
 
Mushroom  Antitumor extracts Cell line Mechanism of action 
Amauroderma 
rude 
Hot water extract 
MT-1 
MDAMB231 
4T1 
MDAMB468 
MCF7 
Induction of apoptosis 
Antrodia 
Camphorate 
Cold water extract 
MDA-MB- 453 
BT-474 
Inhibition of cell growth 
and induction of 
apoptosis through the 
induction of ROS, 
depletion of HER-2/neu, 
and disruption of the 
PI3K/Akt signaling 
pathway 
   
Fermentation culture SKOV-3 
Modulation of HER-
2/neu signaling pathway 
Antrodia 
cinnamonea 
Ethanolic extract WEHI-3  
Inhibition of the 
proliferation and 
migration, MMP-9 
protein expression 
reduction 
Clitocybe 
alexandri 
Ethanolic extract NCI-H460 S-phase cell cycle arrest 
Ganoderma 
lucidum 
Commercially available 
extract Reishi-Max 
GLpTM 
mice injected with 
IBC cells 
Decrease in mRNA and 
protein expression of 
molecules involved in 
PI3K/Akt/mTOR and 
MAPK signaling 
pathways 
Hericium 
erinaceus 
50% ethanol extract 
CT-26 mouse colon 
carcinoma cell 
Suppression of ERK and 
JNK activation, inhibition 
of lung metastasis in vivo 
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Lentinula 
edodes 
Aqueous extract Hep-2 and HeLa Induction of apoptosis  
   
Ethanol extract HepG2  Induction of apoptosis  
Pleurotus 
pulmonarius 
Hot water extract 
Huh7, Hep 3B, 
SMMC-7721 and 
HepG2 
Inhibition of VEGF 
mediated autocrine 
regulation of PI3K/AKT 
Pleurotus 
sajor-caju 
Aqueous extract Hep-2 and HeLa Induction of apoptosis 
Suillus 
collinitus 
Methanolic extract MCF-7  
Increase in  p53 
expression and induction 
of apoptosis 
Suillus luteus Methanolic extract 
MCF-7, NCI-H460, 
AGS, HCT-15  
Increase in  p53 
expression and induction 
of  apoptosis 
Tricholoma 
giganteum 
80% ethanol extract 
Ehrlich ascites 
carcinoma 
Induction of apoptosis 
    
In some countries, such as China, Japan, Korea and other East Asian countries, some 
compounds extracted from mushrooms (namely Lentinan, Schizophyllan, Grifolan and 
Krestin, from Lentinus edodes, Schizophyllum commune, Grifola fondosa and Trametes 
versicolor) have already been approved for their use in clinical treatment in cancer 
patients (Lindequist et al. 2005, Lull et al. 2005, Poucheret et al. 2006, Ferreira et al. 
2010).  
Interestingly, it has been suggested that whole-mushroom extracts contain various 
compounds that may control tumorigenesis and carcinogenesis at different stages 
and/or may act at the same stage but through distinct mechanisms. The multiple 
medical properties of mushrooms might control tumorigenesis and carcinogenesis, 
since some of their compounds are actually capable of reducing tumor initiation by 
different mechanisms, such as enhancing the antioxidant activity (Lee and Nishikawa 
2003). Also the immunomodulation ability documented in other compounds, 
predominantly in polysaccharides, may have an effect on the promotion and 
progression stages of carcinogenesis. Nevertheless, other mushroom compounds could 
inhibit/reduce promotion or progression by exerting direct cytotoxicity against tumor 
cells (Takaku et al. 2001). Therefore, whole-mushroom extracts could offer additional 
effects in the prevention and treatment of cancer (Lull et al. 2005) when applied as 
adjuvants to classical treatment against cancer, synergizing or potentiating 
conventional treatments as chemotherapy (Kimura 2005). 
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1.2.1.2.1. Cordyceps militaris 
 
Cordyceps militaris (Figure 5) is a type of edible Ascomycete, also called “vegetable 
wasp and plant worm”, reported as having potent medical properties (Park et al. 2005, 
Li et al. 2010). It is traditionally used in the Orient for longevity, endurance and vitality 
(Park et al. 2005) being also used  as a crude drug and a folk tonic food for cancer 
patients (Das et al. 2010, Li et al. 2010, Rathee et al. 2012).  
 
Figure 5 - Cordyceps militaris. 
Adapted from (Zheng et al. 2011) and (Das et al. 2010), respectively. 
 
This mushroom is an entomopathogenic fungus, a fungus which infects the larva, pupa 
or imago of insects (killing them), and its fruiting body grows on the larval, pupal or 
adult integument of the insect host (Park et al. 2005, Das et al. 2010).   Although C. 
militaris has a worldwide distribution (probably due to the fact that it adapts to a wide 
range of host insects), its development requires strict growth environment conditions. 
Thus, the population density of C. militaris is very scarce in nature (Shih et al. 2007, 
Das et al. 2010, Shrestha et al. 2012). Although it is mainly an insect pathogenic 
fungus, it may also grow and finish its life cycle in vitro (in non-insect media) (Shrestha 
et al. 2012). Thus, artificial methods of cultivation and production of C. militaris fruiting 
bodies have been developed in the recent years. These cultivated C. militaris, besides 
allowing for a good model for the study of Cordyceps species (Shrestha et al. 2012), 
also possess pharmacological efficacy which is comparable to the natural ones (Rao et 
al. 2010). Moreover, the fact that the genome of C. militaris has already been 
sequenced (Zheng et al. 2011) allowed for a methodical study of the biology and 
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pharmaceutical properties of this mushroom and the identification of potential safety 
hazards (Zheng et al. 2011, Zheng et al. 2013). 
The list of pharmacological activities described for C. militaris is vast and includes the 
following:  anti-inflammatory (Yu et al. 2004, Won and Park 2005, Jo et al. 2010, Rao et 
al. 2010, Han et al. 2011, Ying et al. 2014), antioxidant (Yu et al. 2007, Jiang et al. 2011, 
Wu et al. 2011, Chen et al. 2013, Jeong et al. 2013), antitumor (Reis et al. 2013), anti-
angiogenic (Won and Park 2005), antiproliferative (Liu et al. 1997) and antimetastatic 
(Shih et al. 2007), immunomodulatory (Zhou et al. 2002, Kim et al. 2006, Kim et al. 
2006, Ohta et al. 2007, Kim et al. 2008, Lee and Hong 2011, Jeong et al. 2013, Xiong et 
al. 2013), antimicrobial, antibacterial (Ahn et al. 2000), antiviral (Muller et al. 1991, 
Ohta et al. 2007, Jiang et al. 2011), antifungal (Sugar and McCaffrey 1998, Shih et al. 
2007), mitochondrial protective and anti-aging (Li et al. 2010), anti-malarial (Trigg et al. 
1971), anti-fatigue (Mizuno 1999), protective of the activity of liver , kidney and lung 
(Yu et al. 2007) , among others (Liu et al. 1997, Das et al. 2010). 
 
Regarding the antitumor activity of C. militaris and of some of its compounds, there 
are already several studies published in the literature, some of which will be referred 
in the following subsections.  
 
1.2.1.2.1.1. Water extracts from C. militaris 
 
Water extracts of C. militaris have shown ability to inhibit the growth of human tumor 
cells including: umbilical vein endothelial (HUVEC), human sarcoma (HT 1080) and 
melanoma (B16-F10) cells (Yoo et al. 2004). Furthermore, a water soluble fraction of C. 
militaris showed cytotoxic activity on gastric adenocarcinoma (SNU-1); colorectal 
adenocarcinoma (SUN-C4) and hepatocellular carcinoma (SNH-354) cells (Yue et al. 
2013). 
Treatment with an aqueous extract from this mushroom decreased leukemia cellular 
growth through induction of apoptotic cell death (Lim et al. 2004, Park et al. 2005). 
Likewise, induction of apoptosis following treatment with C. militaris water extracts 
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has also been shown in several other cell line models such as: human breast cancer 
(MDA-MB-231) cells (Jin et al. 2008), human promyelocytic  leukemia  (HL-60) (Lee et 
al. 2006) and  human lung carcinoma (A549) cells (Park et al. 2009).  
Furthermore, hot  water  extracts  from this mushroom also exhibited an 
antiproliferative effect on tumor cells, and prolonged the overall survival  in  mice  
bearing  ascitic  tumors (Lee et al. 2003) or  sarcoma-180  solid  tumors (Lee and Lee 
2004). Also, crude water-soluble polysaccharides extracted from the fruiting bodies of 
this species suppressed the growth of a murine melanoma B16-F10 cell line (Lee and 
Hong 2011). 
Interestingly, treatment of xenografts in nude mice of NCI-H460 cells (non-small cell 
lung cancer cells, NSCLC) with an aqueous extract of C. militaris resulted in tumor 
shrinkage and increased mice lifespan (Park et al. 2009).  
 
1.2.1.2.1.2. Methanolic extract from C. militaris 
 
Regarding the methanolic extracts from C. militaris and their antitumor activity, the 
existing information is still limited. In fact, only two studies seem to have been 
published on this subject. Reis and collaborators showed that a methanolic extract of 
C. militaris fruiting bodies (the one used in this thesis) inhibited proliferation of MCF-7 
(breast adenocarcinoma), NCI-H460 (NSCLC), HCT-15 (colon adenocarcinoma) and 
HeLa (cervical) cell lines (Reis et al. 2013), without affecting non-tumor liver primary 
cells (PLP2). Likewise, Liu and collaborators also observed that methanolic extracts of 
fermented mycelia and fruiting bodies of C. militaris inhibited the growth of HCT-116 
(colon adenocarcinoma), A549 (lung adenocarcinoma), MGC-803 (gastric 
adenocarcinoma), HepG2 (hepatocellular carcinoma), MCF-7 (breast adenocarcinoma) 
and HL-60 (promyelocytic leukemia) cell lines (Liu et al. 2014). 
Nevertheless, the mechanism(s) of action of the methanolic extract of C. militaris, in 
particular of its fruiting body, remain unknown. These may be due to some of its 
potential components, namely cordycepin.  
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1.2.1.2.1.3. Some antitumor compounds isolated from C. militaris  
 
Some of the compounds extracted from C. militaris with antitumor activity have 
already been identified and characterized.  
Cordycepin (which is also isolated from other Cordyceps, Figure 6) is one of the 
compounds isolated from C. militaris. In fact, it is considered by many authors to be a 
key compound for the antitumor activity of C. militaris, although there are other 
studies that showed other isolated compounds with antitumor activity (Liu et al. 2014). 
Cordycepin inhibits the activity of polyadenylate polymerase (PAP) and may abrogate 
mRNA synthesis during the polyadenylation, resulting in cell death (Thomadaki et al. 
2005, Wu et al. 2007, Jeong et al. 2011). It has been shown to be an inducer of 
apoptosis (Thomadaki et al. 2008, Chen et al. 2010, Jeong et al. 2011, Baik et al. 2012, 
Ko et al. 2013) and also to affect cell cycle (Thomadaki et al. 2005, Wu et al. 2007). In 
particular, it was found to cause induced G2/M cell arrest in OEC-M1 (oral cancer) (Wu 
et al. 2007) and in MCF-7 (breast cancer), and to induce S cell arrest in HeLa (cervical 
cancer) cells (Thomadaki et al. 2005). In addition, in vivo studies showed that 
Cordycepin decreased cell growth of B16-BL6 mouse melanoma (Yoshikawa et al. 
2004) and growth of hematogenic metastasis of mouse melanoma cells and mouse 
lung carcinoma cells (Ko et al. 2013). 
 
 
Figure 6 - The chemical structure of cordycepin produced by C. militaris. 
[Extracted From (Tuli et al. 2013)] 
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The peptide Cordymin is another of the compounds isolated from C. militaris which has 
shown anti-proliferative activity in MCF-7 breast cancer cells (Wong et al. 2011). Also, 
MA-1, a synthetic analog of militarin, inhibited the viability of several cell lines (namely 
A549, H358, and NCI-H460) by inhibiting cell growth and inducing apoptosis (Yoon et 
al. 2013). In addition, CMP-1, a low-molecular-weight polysaccharide inhibited 
proliferation of HT-29, HeLa, HepG2 and K562 cells (Jing et al. 2014). 
 
1.2.2. Mushrooms as natural source of compounds with immunomodulatory activity 
 
The stimulation of immune response leads the improvement of body's defense 
mechanisms, therefore playing a crucial role in the prevention and/or treatment of 
diseases, including cancer (Zitvogel et al. 2008, Zhou et al. 2009, Lee and Hong 2011).  
The strategy behind the use of immunomodulation in therapy consists of identifying 
aspects of the host response that can be changed, resulting in an increase of the 
desired immune response (Zaidman et al. 2005). 
Immunomodulators, also known as “biological response modifiers”, 
“immunopotentiators” or “immunostimulants”, are able to stimulate or inhibit the 
immune system (Moradali et al. 2007, Rathee et al. 2012). This enhancement or 
suppression of immune responses is dependent on the dose, route of administration, 
time of administration, mechanism of action and site of activity of the 
immunomodulators (Moradali et al. 2007, Rathee et al. 2012).  
 
1.2.2.1 The immune system: general remarks 
 
The immune system is a complex system (involving different organs, tissues, cells and 
their soluble products) which plays the important and indispensable role of protection 
and defense, against non-self entities like infectious agents (such as bacteria, 
microbes, viruses, toxins and parasites) as well as maintenance of the body 
homeostasis in response to endogenous signals (Mak et al. 2005). This complex system 
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recognizes attacks and destroys everything that is considered as harmful to the body 
(Mak et al. 2005). When the immune system fails, several pathologies or adverse 
reactions may be triggered. 
 An abnormal immune system may attack the body’s cells and tissues resulting in 
autoimmune diseases. It may also react against an antigen that is generally harmless, 
culminating in allergic reactions. When the immune reaction is too strong or 
dysregulated, it may result in hypersensibility against the antigen.  Finally, when the 
immune system is decreased (naturally or induced by external factors) 
immunodeficiency occurs in the host, compromising the natural health balance (Mak 
et al. 2005).   
The immune response is affected by several factors (such as age, gender, endocrine 
factors, stress, environment and health condition (Cohen et al. 1991, Brabin 2002, 
Srinivasan et al. 2005)) and is divided in two different types of response: the innate 
and the adaptive, which are not mutually exclusive. These two different types of 
immune response differ in degree of specificity and also in the mechanisms activated 
(Mak et al. 2005). The innate immunity response provides for an immediate response, 
although being less-specific than the adaptive response. On the other hand, the 
adaptive response is activated by the innate response, providing a stronger and highly 
specific response, being able to develop memory (recalling specific intruders and 
producing a faster and stronger response in later challenges (Litman et al. 2005)). 
In innate immunity, the monocytes, macrophages, neutrophils, dendritic cells (DC) and 
natural killer (NK) cells respond quickly to molecular patterns and some of them 
(monocytes, macrophages and DC) present particular antigens.  This response does not 
result in long-term immunity; however, it may lead to the activation of long-lasting 
pathogen-specific response of the adaptive immune system (Lin et al. 2009). Innate 
immune cells recognize and destroy atypical cells. These events occur by the 
stimulation of macrophages (with their activation) and NK cells in order to produce 
cytokines, interleukins and other inflammatory regulator molecules that are targeted 
towards destroying abnormal cells (Moradali et al. 2007, van Griensven and Verhoeven 
2013). 
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Macrophages are mononuclear differentiated cells originated from blood monocytes, 
which are key players in immune response since they respond quickly against 
pathogens. When macrophages are activated, they produce inflammatory regulators, 
such as cytokines, COX-2, prostaglandins and nitric oxide, which in turn activate the 
MAPK dependent signaling pathways and NF-κB dependent transcription regulation 
(van Griensven and Verhoeven 2013). In innate immunity, when reaching the target 
tissues (Mosser and Edwards 2008), they may have different functions, such as killing, 
phagocyting and removing pathogenic microbes. Macrophages also play an important 
role in the adaptive immunity, by presenting antigens to lymphocytes and by 
regulating lymphocyte activation and proliferation (Elhelu 1983, Shin et al. 2010).  
1.2.2.2. Examples of mushrooms with immunomodulatory activity 
 
The therapeutic effects of several mushrooms may be related (directly or indirectly) to 
the enhancement of immunity of the host (Roupas et al. 2012). In the last decades, the 
study of mushrooms as natural sources of compounds with low toxicity and high 
capacity to activate the immune system has been increasing (Mizuno and Nishitani 
2013). Moreover, their ability to modify the immune response has already been 
proven (Zaidman et al. 2005, Hilszczańska 2012). In fact, mushroom-isolated 
compounds with immunodulatory potential exert their activity through: i) 
mitogenicity, ii) activation of alternative complement pathway or iii) stimulation of 
immune effector cells from the innate and adaptive immunity [such as hematopoietic 
stem cells, macrophages, lymphocytes, T cells (T helper cells and T cytotoxic cells), 
dendritic cells, and natural killer cells resulting in the production of cytokines] (Lull et 
al. 2005, Moradali et al. 2007).   
Some of the mushroom-extracted compounds considered as immunomodulators are: 
polysaccharides, glycoproteins, glycopeptides, proteoglycans, fungal 
immunomodulatory proteins (Fips) and triterpenoids. These molecules are able to 
affect the proliferation and differentiation of immune cells, and also of cytokines and 
interleukins, thus enhancing the innate and adaptive immune responses (Moradali et 
al. 2007). Polysaccharides act via the innate immunity, mediated by the release of 
cytokines which later will stimulate the adaptive immunity (Brown and Gordon 2003, 
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Volman et al. 2010), increasing the host ability to resist against virus, bacteria and 
other intruders (Zheng et al. 2005). β-Glucans are considered the most important 
polysaccharides with immunomodulary activity without presenting adverse effects 
(Zheng et al. 2005, Ramberg et al. 2010, Mizuno and Nishitani 2013). β-Glucans have 
been proved to increase phagocytosis activity, nitric oxide production, catalase activity 
of macrophages and to reduce tumor formation in a mouse model (Zheng et al. 2005, 
Ramberg et al. 2010).  
Different studies have proven that different mushroom extracts and compounds exert 
effect on macrophages, by activating them to produce mediators (Lull et al. 2005). 
Table 3 - Some immunomodulatory compounds extracted from mushrooms 
[Adapted from (Lindequist et al. 2005)] 
 
Mushroom  Immunomodulator compound 
Agaricus brasiliensis FIo-a-β 
FA-2-b-Md 
Cryptoporus volvatus H-3-B 
Flammulina velutipes Flammulin 
Ganoderma lucidum GLP(AI), Ganopoly, Ganoderans 
Protein LZ 8 
Grifola frondosa MD-fraction 
Grifolan 
Lentinus edodes Lentinan, KS-2 
LEM 
Lentinus strigellus Polysaccharides 
Phellinus linteus Polysaccharides 
Schizophyllum commune Schizophyllan, Sonifilan 
Sparassis crispa SCG 
Trametes versicolor PSK, PSP 
Tremella fuciformis Tremellastin 
Tricholoma lobayense Polysaccharide–peptide complex 
Tricholoma mongolicum Lectin 
FIo-a-β and FA-2-b-Md: water-soluble fractions from the fruiting body of Agaricus blazei; H-3-B: A water-
soluble (1 → 6) -branched (1 → 3)-β-d-glucan, isolated from a hot-water extract of the fruiting bodies of 
Cryptoporus volvatus; GLP(AI): polysaccharide fraction  of hot-water extract of the mycelium 
of Ganoderma lucidum; MD-fraction: Maitake (Grifola frondosa) D-Fraction; KS-2 : polysaccharide 
extracted from culture mycelia of Lentinus edodes; LEM: Complex mixture of polysaccharides and lignin 
from Lentinus edodes mycelia; SCG: purified β-glucan preparation from Sparassis crispa; PSK: semi-
purified polysaccharide peptide Krestin from Trametes versicolor; PSP:polysaccharopeptide 
from Trametes versicolor 
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1.2.2.2.1. Suillus luteus 
 
Suillus luteus (Figure 7) in an edible mycorrhizal mushroom (decomposers of organic 
matter, forms mycorrhizal associations with plant roots) species from Northeast 
Portugal. The symbiosis of this mushroom with the vegetation and soils may possibly 
influence the production of metabolites, including bioactive compounds (Crabtree et 
al. 2010, Reis et al. 2011). There are already some published studies showing the  
biological activity of S. luteus extracts, including antitumoral (Santos et al. 2013, Jia et 
al. 2014, Santos et al. 2014) and antioxidant (Reis et al. 2011). However, its potential 
as immunomodulator has not been previously addressed. 
 
Figure 7 - Suillus luteus 
Adapted from (Ostry et al. 2011). 
 
 
1.2.2.2.2. Morchella esculenta 
 
Morchella esculenta (Figure 8), one of the most widely appreciated (although rare) 
wild edible mushrooms, is characterized by a hollow fruit body. This mushroom has a 
huge potential value in China where it is used in traditional medicine for indigestion, 
excessive phlegm and shortness of breath (Duncan et al. 2002, Prasad et al. 2002, Cui 
et al. 2011, Fu et al. 2013, Li et al. 2013).  
The main nutritional components of M. esculenta are protein, fat, fiber, ash and 
carbohydrates (Xu et al. 2008), with its principal biological active compounds being 
polysaccharides, proteins, trace elements, dietary fiber and vitamins (Cui et al. 2011). 
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Figure 8- Morchella esculenta 
Adapted from (Ostry et al. 2011) 
 
 
Previous studies have shown some of the biological activities of M. esculenta, namely 
antioxidant (Mau et al. 2004, Elmastas et al. 2006, Meng et al. 2010) anti-inflammatory 
(Nitha et al. 2007), antimicrobial (Kalyoncu et al. 2010, Heleno et al. 2013) and 
antitumor (Nitha et al. 2007).  
Additionally, some work has been previously published on the immunomodulatory 
activity of some of the M. esculenta extracts or isolated compounds. Indeed, two 
water-soluble polysaccharides (MEPs) from the fermentation broth of M. esculenta 
were shown to significantly modulate the immune activity by selectively activating T 
cells and purified lymphocytes (Cui et al. 2011). In addition, galactomannan, a 
compound extracted from M. esculenta, enhanced macrophage activation (Duncan et 
al. 2002). 
 
Overall, it is clear that several edible mushrooms possess some attractive compounds 
which have tonic and medicinal qualities.  Although there are already several studies 
on the antitumor and immunomodulatory potential of mushrooms, there are still 
many mushrooms species whose properties have not yet been thoroughly studied, in 
particular their mechanism of action. This may be important for the identification of 
new therapeutic strategies. 
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As already mentioned, several mushrooms are an unlimited source of compounds with 
recognized antitumor and immunomodulatory activities. However, the potential of 
some mushrooms remains unknown, and for others their mechanism of action is still 
unidentified.  
A recent study from external collaborators of the supervisors of this study has 
identified a methanolic extract from Cordyceps militaris as an inhibitor of the growth 
of human tumor cell lines, particularly of a non-small lung cancer cell line (NCI-H460) 
(Reis et al. 2013). Nevertheless, its mechanism of action remained unknown. 
Therefore, the first aim of the present work was to study the mechanism of action of 
the methanolic extract of Cordyceps militaris in the NCI-H460 cells, specifically 
regarding effect on:  
- Cellular proliferation 
- Cell cycle profile 
- Cellular apoptosis 
- DNA damage 
This cell line was chosen based on the fact that: i) in the above mentioned study it was 
one of the most sensitive cell lines to the effect of the extract; ii) it is representative of 
a type of cancer that is still responsible for many deaths and iii) it has wild-type p53 
which would allow studying p53-dependent mechanisms of action. 
The second aim of this work was to study the immunomodulatory activity of two 
mushrooms extracts: i) a polysachararidic (PLS) extract of Suillus luteus, and ii) a 
phenolic extract of Morchella esculenta. For this, the THP-1 human monocytic cell line 
was used as a model, since these cells behave like monocytes and, upon stimulation 
they may differentiate into machrophages (immunologically active cells) (Auwerx 
1991). In particular, it was intended to analyse the effect of the referred extracts in 
THP-1 cellular proliferation and differentiation .
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3.1. Mushroom extracts 
 
The following mushroom extracts were used: i) a methanolic extract of Cordyceps 
militaris, ii) a polysaccharidic (PLS) extract of Suillus luteus and a phenolic extract of 
Morchella esculenta. All the extracts used in this work were prepared and kindly 
provided by Prof. Doctor Isabel Ferreira from Instituto Politécnico de Bragança (IPB), 
Portugal. 
The methanolic extract of C. militaris had been previously obtained by collaborators of 
the group from cultivated fruiting bodies of C. militaris (L.) Link (strain: MCI 10304, 
Meshtech Cordyceps Institute), as published in Reis et al. (2013). A stock solution at 8 
mg/mL in H2O was stored at -20ºC.  
The polysaccharidic (PLS) extract of S. luteus was obtained from samples of S. luteus 
(L.: Fries) Gray, collected in Bragança (Portugal) by the same collaborators of the group 
(Santos et al. 2013).  
Like the other extracts, also the phenolic extract of Morchella esculenta had been 
obtained by the same collaborators. This extract was obtained from specimens of 
Morchella esculenta (L.) Pers. collected in Bragança (Portugal) (Heleno et al. 2013).  
The stock solution of PLS extract from Suillus luteus and phenolic extract from 
Morchella esculenta were prepared at 50 mg/mL in H2O and stored at -20
oC. 
 
3.2. Cell Culture  
 
All the procedures involving cell culture were carried out in a biosafety level II laminar 
flow cabinet (Telstar Bio II Advance). 
The following cell lines were used: NCI-H460 (NSCLC, adherent) and THP-1 (human 
leukaemia monocytic cell line from peripheral blood; in suspension). Cells were 
routinely maintained in culture in 25 cm2 or 75 cm2 tissue culture flasks, in RPMI 
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(Roswell Park Memorial Institute) 1640 medium with UltraGlutamine I and 25mM 
HEPES (Lonza), supplemented with 10% fetal bovine serum (FBS; Biowest), and 
incubated at 37oC in a humidified atmosphere with 5% CO2.  NCI-H460 cells were split 
twice per week (when confluency reached approximately 80%). For this, cell medium 
was discarded and cells washed with phosphate buffered saline (PBS; 1ml) to remove 
trypsin inhibitors. Trypsin-EDTA (0.5ml; Lonza) was then added and incubated for 10 
min at 37 oC to allow cell detachment (Gilbert et al. 2006). Complete medium was 
added to inactivate trypsin and the following procedures were carried out: i) when 
starting an experiment,  cells were centrifuged, medium discarded and cells 
resuspended in fresh medium at the desired concentration and ii) for routine 
maintenance, cells were diluted 1:20 and seeded into a new 25 cm2 flask.  
Regarding the THP-1 suspension cells, cells were sub-cultured twice per week. For this, 
cells were centrifuged at 1500 rpm from 5 minutes and resuspended in fresh medium 
at a 3 x 105 cell/ml. 
To induce THP-1 differentiation from monocytes into macrophages, cells were 
incubated with 20 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich), for 18 
h at 37 oC and 5% CO2. After incubation, medium with PMA was removed, cells were 
washed with PBS, and further incubated for 24 h in fresh medium without PMA to 
induce maturation (Tsuchiya et al. 1982, Takashiba et al. 1999, Roussaki et al. 2012). 
 
3.2.1. Cell number and viability - Trypan blue exclusion assay 
 
Cell number and viability were evaluated using Trypan blue exclusion assay. This dye 
allows distinguishing viable cells (which exclude the dye, since their cell membrane is 
intact) from death cells (which take up the dye, since the membrane permeability is 
already compromised). Cell suspension was mixed 1:1 with a trypan blue solution 
(0.2%; Sigma-Aldrich) and loaded into a Neubauer chamber. The number of cells 
(stained and unstained) was counted under a bright-field microscope (Nikon Alphaphot 
2 YS2) and cell density (number of cells/mL) was determined using the following 
formula:  number of viable cells/field x dilution factor x 104. In addition, the percentage 
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of viability (corresponding to the ratio of the number of viable cells and the number of 
total of cells x 100) was also determined.  
All experiments were performed with exponentially growing cells which presented 
viabilities higher than 90%.  
Throughout all the experiments, cells were daily observed under an inverted 
microscope (Nikon Eclipse TS100) to assess their morphological features and to avoid 
contaminations.  
 
3.3. Analysis of the effect of methanolic extract of Cordyceps 
militaris in NCI-H460 cells 
 
In this part of the study, the NCI-H460 cell line was used. Cells (1 x 105/well) were 
plated in 6-well plates (TPP Techno Plastic Products) and incubated for 24 hours at 37 
oC in 5% CO2 to allow cell adhesion. After 24 h incubation, cells were treated with the 
methanolic extract either at its GI50 (concentration of extract that reduced cell growth 
to 50%), previously determined to be approximately 50 μg/mL (Reis et al. 2013), with 
twice this concentration (100 μg/mL), or with half the GI50 concentration (½ GI50; 25 
μg/mL).  The following controls were also included: Blank (cells treated with medium 
only) and vehicle control (H2O, in an equivalent concentration to concentrations of 
extract used). Following 48 h treatment, the medium was removed (but not discarded) 
and cells were trypsinised. The previously removed medium was then used to 
inactivate trypsin and the cell suspension was centrifuged at 1200 rpm for 5 minutes in 
a centrifuge (MPW 350R, Med. Instruments). Cell pellets were further processed 
according to the procedures described below. 
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3.3.1. Analysis of cellular proliferation with the BrdU incorporation assay 
 
For the analysis of cellular proliferation, the BrdU (5-bromo-2'-deoxyuridine) 
incorporation assay was carried out as follows.  Following 47 h incubation with the 
extract, cells were incubated for 1 h with 10 μM BrdU (Sigma Aldrich) at 37 °C and 5% 
CO2. Cell pellets were then obtained (as previously described in section 3.3 “Analysis of 
the effect of methanolic extract of C. militaris in NCI-H460 cells”) washed in PBS and 
fixed in 4% paraformaldehyde (PFA; Merck) in PBS for 30 minutes at room 
temperature. Cells were then centrifuged and cell pellets were resuspended in PBS and 
kept at 4oC until processed. For analysis, cell cytospins were prepared by centrifuging 
cells at 500 rpm for 5 min in a cytospin centrifuge (Shandon Cytospin 3). Cells were 
washed 3 times with PBS and incubated in 2 M HCl at room temperature for 20 
minutes, for DNA denaturation. Subsequently, cells were washed twice in PBS, twice in 
PBS-T-B [PBS, 0.5% Tween 20 (Promega), 0.05% BSA (Sigma Aldrich)] and incubated 
with mouse anti-BrdU antibody (1/10 dilution in PBS-T-B; Dako) for 1 hour at room 
temperature. After being washed twice in PBS-T-B, cells were incubated with anti-
mouse-Ig-FITC (diluted 1/100 in PBS-T-B: Dako) for 30 minutes, at room temperature 
(in the dark). Cells were then washed again twice with PBS-T-B and slides were 
prepared with Vectashield mounting medium with 4',6-diamidino-2-
phenylindoledihydrochloride (DAPI) (Vector laboratories). BrdU incorporation was 
analyzed using a fluorescence microscope (Leica DM2000). A semi-quantitative 
evaluation of the levels of proliferation was carried out by counting at least 500 cells 
per treatment and determining the percentage of FITC-stained nuclei in the total DAPI-
stained nuclei. 
 
3.3.2. Analysis of cell cycle profile by Flow cytometry 
 
Cell cycle profile was analyzed by flow cytometry after staining with propidium iodide 
(PI). Cell pellets (obtained as previously described in section 3.3 “Analysis of the effect 
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of methanolic extract of C. militaris in NCI-H460 cells”) were immediately fixed in 2 mL 
ice-cold 70% ethanol (Carlo Erba Reagents) and stored at 4oC for at least 12 h before 
being analyzed.  Cells were then centrifuged for 5 min at 1200 rpm and resuspended in 
a solution of PBS with 5 μg/mL PI (Sigma-Aldrich) and 0.1 mg/mL RNase A (Sigma-
Aldrich). Cellular DNA content was measured by flow cytometry using a FACSCalibur 
flow cytometer (Becton Dickinson, USA). The percentage of cells in the G1, S and G2/M 
phases of the cell cycle (as well as the percentage of cells in the sub-G1 peak) were 
determined using the FlowJo 7.6.5 software (Tree Star, Inc., Ashland, OR, USA) after 
cell debris and aggregates exclusion and plotting at least 20.000 events per sample.  
 
3.3.3. Analysis of apoptosis by Flow cytometry 
 
For the analysis of apoptotic cell death, the Annexin V-FITC Apoptosis Detection kit 
(eBioscience Dx Diagnostics) was used. Cell pellets (obtained as previously described in 
section 3.3 “Analysis of the effect of methanolic extract of C. militaris in NCI-H460 
cells”) were resuspended in 400 μL binding buffer (previously diluted 1:4 in water). 
Samples were then divided in two parts, the first corresponding to the 
“autofluorescence” and the second corresponding to the incubated with Annexin V-
FITC/PI which was further processed as follows. Cell suspension (195 μl) was incubated 
with Annexin V-FITC (5 μL) for 10 min at room temperature, in the dark. Propidium 
iodide (10μL) was then added and further incubated at room temperature for 2 min in 
the dark. Samples were immediately analyzed for the staining of Annexin V-FITC/PI by 
flow cytometry using a FACSCalibur flow cytometer (BD Biosciences, USA) plotting at 
least 20.000 events per sample. Data was analyzed using FlowJo 7.6.5 software (Tree 
Star, Inc., Ashland, USA) after cell debris exclusion. 
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3.3.4. Analysis of protein expression 
 
3.3.4.1. Total protein extraction and protein quantification 
 
Cell pellets (obtained as previously described in section 3.3 “Analysis of the effect of 
methanolic extract of C. militaris in NCI-H460 cells”) were lysed in Winman´s Buffer 
(50mM EDTA; 1.5M NaCl; 1% NP-40; 1 M Tris-HCl) supplemented with EDTA-free 
protease inhibitor cocktail (Roche), for 45 min at 4oC with agitation. Cell lysates were 
centrifuged at 4oC for 10 minutes at 13.000 rpm and the pellet discarded. Protein 
lysates were kept on ice until quantification (or stored at -20 oC).  
The quantification of the total protein content was carried out using “Bio-Rad´s DC 
Protein Assay” kit (Bio-Rad). For this, a standard curve was prepared, using serial 
dilutions of bovine serum albumin (ranging from 0 µg/mL to 3000 µg/ml). Briefly, a 
volume of 5 µl of protein lysate (or standards) was platted (in duplicate) in a 96 well 
plate (Orange Scientific). To each well, 25 μl of reagent A´ (prepared by adding 20 μl of 
reagent S to 1mL of reagent A) and then 200 µl of reagent B were added. The plate was 
gently agitated and incubated for 15 min at RT in the dark. Absorbance was then read 
at 655 nm in a multiplate reader (BioTek® Synergy HT). 
 
3.3.4.2. Western blot 
 
For the analysis of protein expression, Western blot was carried out. For this, protein 
samples were prepared by mixing protein lysates (30 µg) with loading buffer [10% 
sodium dodecyl sulfate (SDS), 1.0 M Tris-HCl, 50% Glycerol, 10% β-mercaptoethanol, 
1% bromophenol blue]. After being denaturated at 95 oC for 5 minutes, proteins were 
loaded and electroforetically separated in a 12% Bis-Tris SDS-PAGE gel (Sambrook et al. 
1982). A protein molecular weight marker (BioRad) was also loaded in each gel. 
Proteins were electrophoretically transferred to a Hybond-C Extra nitrocellulose 
membrane (Amersham Biosciences) at 100 V during 1 h and 30 minutes. Membranes 
were blocked for 1 hour at RT (or overnight at 4 oC) in TBS-T [TBS (137 mM NaCl; 3 mM 
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KCl; 25 mM Tris-Base; H2O) with 0.1% of Tween-20 (Promega)] containing 5% skimmed 
milk (Molico, Nestlé). After blocking, membranes were incubated with the following 
primary antibodies: rabbit anti-PARP (1:2000; Santa Cruz Biotechnology); mouse anti-
p53 (1:200; Neomarkers); mouse anti-p21 (1:250; Calbiochem); rabbit anti-PH2Ax 
(1:200; Santa Cruz Biotechnology) or goat anti-actin (1:2000; Santa Cruz 
Biotechnology). Incubations were for 1 h 30 min at RT (for PARP, p53, P-H2Ax and 
actin) or overnight at 4oC (for p21). Membranes were washed with TBS-T and then 
further incubated with the respective following secondary antibodies: goat anti-rabbit-
IgG-HRP; goat anti-mouse-IgG-HRP or donkey anti-goat-IgG-HRP (1:2000; Santa Cruz 
Biotechnology) for 1 hour at RT. Protein signals were detected by chemiluminescence 
using the ECL Western blot Detection kit (GE Healthcare), the Amersham Hyperfilm ECL 
(GE Healthcare) and Kodak’s GBX developer and fixer (Sigma-Aldrich).  For the analysis 
of some proteins, membranes were striped for 30 minutes at 50 oC in stripping buffer 
(1 M Tris-HCl, 14.3 M β-Mercaptoethanol and 10 % SDS), washed in TBS-T, blocked in 5 
% skimmed milk (Molico, Nestlé) in TBS-T, as previously described and reprobed with 
the specific antibody. The intensity of the bands obtained in each film was quantified 
using the Quantity One software (BioRad). 
 
3.3.5. Analysis of 53BP1 expression by Immunofluorescence 
 
Cells pellets (obtained as described in section 3.3 “Analysis of the effect of methanolic 
extract of C. militaris in NCI-H460 cells”) were washed in PBS and fixed in 4% 
paraformaldehyde (Merck) in PBS for 30 minutes at room temperature. Cells were 
then centrifuged and cell pellets were resuspended in PBS and kept at 4oC until 
analysis. For analysis, cell cytospins were prepared by centrifuging at 500 rpm for 5 
min in a cytospin centrifuge (Shandon).  Cells were then incubated with 50 mM NH4Cl 
for 10 minutes, permeabilized with 0,2% Triton X-100 in PBS for 10 minutes and 
further incubated for 20 minutes in blocking buffer (2% BSA in PBS). Cells were 
incubated with rabbit anti-53BP1 antibody (1:200, Santa Cruz Biotechnology) at 4 oC 
overnight, washed in 2% BSA (in PBS), and then incubated for 1 h with rabbit-IgG-FITC 
antibody (1:100; Dako). Slides were mounted with Vectashield mounting media with 
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DAPI (Vector laboratories) and images of the cells were taken (by Diana Sousa at 
IPATIMUP) using a fluorescence microscope (ZEISS Axio Imager.Z1) coupled with 
ApoTome Imaging System microscope. Exported images in TIFF format were 
decompressed with Irfanview (ver. 4.35, Irfan Skiljan, Vienna, Austria) and analyzed 
with ImageJ (version 1.46r, http://rsbweb.nih.gov/ij/index.html). This was carried out 
using a program written by Dr. Niklas Schultz (GMT Department, Stockholm University, 
Sweden (Markova et al. 2007)) which analyses DAPI and FITC channels independently, 
detects cell nuclei and registers foci parameters within the nuclear area. Different 
parameters, including the number of foci per nucleus were given in the output file. 
 
3.4. Analysis of the effect of extracts from Suillus luteus and 
Morchella esculenta in THP-1 cell line 
 
The effect of extracts from Suillus luteus and Morchella esculenta in THP-1 cell line 
were tested following two different protocols: i) MTS assay, for THP-1 monocytes and 
ii) Sulforhodamine B assay, for THP-1 differentiated macrophages. 
 
3.4.1. MTS assay   
 
For the MTS assay, the “CellTiter 96® AQueous One Solution Cell Proliferation Assay” 
(Promega) was used. THP-1 cells (50 μl) were plated at 1 x 104 cell/well in 96-well 
plates (TPP-Techno Plastic Products) and treated with 50 μl of: complete medium 
(blank), five serial dilutions of each extract (ranging from 25 μg/mL to 400 μg/mL), or 
with maximum concentration of the vehicle tested (H2O, control). Following 48 h 
incubation, MTS (20μl) was added to each well and incubated for 1-3 h at 37 oC in 5% 
CO2. Absorbance was measured at 490 nm in a multiplate reader (BioTek® Synergy HT). 
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3.4.2. Sulforhodamine B assay (SRB) 
 
Cells (100μl) were plated in 96-well plates (TPP-Techno Plastic Products) in cell culture 
medium with 20 ng/mL phorbol 12-myristate 13-acetate (PMA; Sigma-Aldrich) for 18 h 
at 37⁰C in 5% CO2, to induce differentiation. Cell culture medium was then replaced 
with fresh medium without PMA and cells incubated for 24 h to induce maturation 
(Roussaki et al. 2012). Cells were then treated with: medium only (100 μl) or with five 
serial dilutions of each extract (in duplicate) ranging from 25 μg/ml to 400 μg/ml. 
Another plate, called the “ T0 plate” to which medium was added, was fixed at this 
point and further processed as explained below for the other plates. The remaining 
plates were incubated for 48 h, being then fixed by the addition of 50 μL ice-cold 10 % 
TCA (w/v) for 1 hour in ice and further washed 3 times with distilled water. After 
drying, plates were stained with 1% SRB in 1% (v/v) acetic acid and washed with 1% 
acetic acid. The bound SRB was solubilised in 10mM Tris-base solution (100μl) and the 
absorbance was measured at 510 nm in a multiplate reader (BioTek® Synergy HT). 
3.5. Statistical analysis 
 
For each assay, more than three independent experiments were carried out, unless 
otherwise stated in the results section. Statistical analysis was carried out using the 
Student's t-test. Differences were considered statistically significant whenever P ≤ 
0.05. 
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The present work was divided into two different parts: i) Part I, consisting in the study 
of the mechanism of action of C. militaris methanolic extract in the NCI-H460 cell line 
and ii) Part II, consisting in the study of the immunomodulatory activity of two extracts 
from different mushrooms, a polysacharidic extract from Suillus luteus and a phenolic 
extract from Morchella esculenta.  
Therefore, the results will be presented and discussed in two different sections. 
Results - Part I 
4.1. Study of the mechanism of action of Cordyceps militaris 
methanolic extract in the NCI-H460 cell line  
 
The first part of the current project aimed at elucidating the mechanism of action of 
the methanolic extract of C. militaris (L.) Link fruiting body. As mentioned in the 
introduction, C. militaris has been regarded as having antitumor properties (Ng and 
Wang 2005). Several previous studies proved that this mushroom and their extracts 
have anticancer activity, with some compounds having been identified as contributors 
to this activity (e.g. cordycepin) (Paterson 2008, Liu et al. 2014). However, very few 
studies referred in particular to the antitumor potential of the methanolic extracts of 
C. militaris. Based on a previous study, from some of the collaborators of the research 
group, which showed that this extract presented antiproliferative potential in a panel 
of human tumor cell lines, including: MCF-7 (breast adenocarcinoma), HCT-15 (colon 
adenocarcinoma), HeLa (cervical adenocarcinoma) and NCI-H460 (NSCLC) (Reis et al. 
2013), it was decided to further study its effect in the cell line in which it was most 
potent (NCI-H460). The choice of this cell line model had also into consideration the 
fact that it is representative of a type of cancer which is responsible for many deaths. 
In addition, this cell line has wild-type p53 which would allow detecting p53-dependent 
mechanisms of action. 
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4.1.1. Effect of C. militaris methanolic extract on NCI-H460 viable cell 
number 
 
In order to confirm that the methanolic extract affected the viability of NCI-H460 cells, 
a preliminary experiment was carried out in which cells were treated for 48 h with C. 
militaris methanolic extract. To observe a possible dose/response effect, two 
concentrations were selected, 50 μg/mL [corresponding to the GI50 concentration 
previously determined as being 47.8 μg/mL (Reis et al. 2013)] and 100 μg/mL 
[corresponding to twice the GI50 (2xGI50)]. Results, obtained after counting the number 
of viable cells with trypan blue (and analyzing results in relation to the number of 
viable cells in the blank, treated with medium only) showed a dose-dependent 
reduction in viable cell number, to 26.0% following treatment with 50 μg/mL and to 
5.6% following treatment with 100 μg/mL (Figure 9).  
 
 
Figure 9 –Effect of C. militaris methanolic extract in NCI-H460 viable cell number, analysed 
with Trypan Blue exclusion assay (Preliminary experiment). 
Cells were treated for 48 h with 50 μg/ml (corresponding to the GI50 concentration) and 100 μg/ml 
(corresponding to the 2xGI50 concentration) of the extract. Results are presented as a percentage of 
viable cells in relation to blank cells (treated with medium only) and are from one experiment only. 
 
These results showed that treatment with 50 μg/mL (GI50) was causing a greater 
reduction of viable cell number than expected (since the GI50 concentration reduces 
cell growth by 50%). The observed discrepancy between the GI50 concentration 
previously determined by our collaborators with the sulforhodamine B (SRB) (Reis et 
al. 2013) and the viable cell number obtained with that same concentration is not 
abnormal in this type of studies and may be explained by the differences in the 
0 
20 
40 
60 
80 
100 
120 
Blank 50 μg/ml 100 μg/ml 
%
 v
ia
b
le
 c
e
lls
 in
 r
e
la
ti
o
n
 t
o
 
B
la
n
k 
C. militaris 
Results and Discussion Chapter IV 
 
 
49 
 
methodologies used in both studies. Indeed, the SRB (which was carried out in the 
study by Reis et al. to determine the GI50 concentration (Reis et al. 2013)) was carried 
out in 5% FBS culture medium, whereas all the assays carried out in the present study 
were performed in 10% FBS supplemented medium.   
Based on the result of this preliminary experiment, it was decided to lower the 
concentration of extract and therefore analyze also the effect of 25 μg/mL 
(corresponding to ½ GI50). Results showed a dose-dependent decrease in the 
percentage of viable cells to 45.8% and 31.1% following treatment with ½ GI50 (25 
μg/mL) and GI50 (50 μg/mL), respectively (when compared to blank cells) (Figure 10). 
As expected, treatment with the solvent, water, at both concentrations [H2O (1) and 
H2O (2)], had no effect in NCI-H460 cells viability. 
 
Figure 10 - Effect of C. militaris methanolic extract in NCI-H460 viable cell number, analysed 
with Trypan Blue exclusion assay. 
Cells were treated for 48h with 25 μg/ml (corresponding to the ½ Gi50 concentration) and 50 μg/ml (GI50 
concentration) of the extract; with the corresponding volumes of solvent [H20 (1) and H2O(2), 
respectively] or with medium only (Blank). Results are presented as percentage of viable cells in relation 
to blank cells and are the mean ± SEM of 6 independent experiments. *P ≤ 0.001 between each 
treatment and the Blank. 
 
In order to further gain insight into the mechanism of action of the extract, these two 
concentrations of extract (25 μg/ml and 50 μg/ml) were used in the following 
experiments. 
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4.1.2. Effect of C. militaris methanolic extract on NCI-H460 cellular 
proliferation 
 
To understand if the extract was affecting proliferation of NCI-H460 cells, BrdU 
incorporation was analysed by fluorescence microscopy, 48 h after treatment of cells 
with the extract. BrdU incorporation assay is based on the fact that cells can easily and 
specifically incorporate BrdU (a thymidine analog) into their newly synthesized DNA 
strands during cell proliferation (cells in S phase), which allows to monitorize DNA 
synthesis and cell proliferation. This incorporation can be easily detected, following 
partial denaturation of double stranded DNA, using FITC-labelled monoclonal 
antibodies against BrdU (Nagashima et al. 1985, Jayat and Ratinaud 1993, Moussa et 
al. 2005).  
Results from this assay showed that the extract significantly decreased NCI-H460 
cellular proliferation in a dose-dependent manner (Figure 11).  
 
Figure 11- Effect of C. militaris in NCI-H460 cellular proliferation, analysed with the BrdU 
assay. 
Cells were treated for 48h with medium only (Blank), with the highest volume of H2O used (control), 
with 25μg/ml or 50μg/ml of C. militaris methanolic extract, or with. Proliferating cell nuclei are stained 
in green (from FITC labelling) and cell nuclei are stained in blue (from DAPI labelling). 
Immunofluorescence microscopy images are representative of three independent experiments.  
*P ≤ 0.001 between each treatment and the Blank. Bar corresponds to 20 μm. 
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A decrease to 21.1% in the percentage of BrdU incorporating cells (compared to 32.0% 
in blank cells) was observed following treatment with 25 μg/ml of C. militaris 
methanolic extract. This decrease in the percentage of NCI-H460 cells undergoing 
proliferation was even more evident following treatment with 50 μg/ml, in which the 
levels of proliferation were 4.1%. As expected, control treatments with vehicle solvent 
had no effect on cellular proliferation.  
 
4.1.3. Effect of C. militaris methanolic extract on NCI-H460 cell cycle 
profile 
 
Given that a decrease in cellular proliferation might indicate that the extract affected 
the normal cell cycle progression, the cell cycle profile of NCI-H460 cells treated with 
the extract was analyzed by flow cytometry using propidium iodide (PI) labelling. This 
assay is based in the fact that PI binds stoichiometrically to nucleic acids. Since it is 
known that PI fluorescence in the cell is proportional to its content, it can be inferred 
that cells in G2/M phase have approximately twice the fluorescence of cells in G0/G1 
phase (Nunez 2001). Flow cytometry analysis following PI labelling therefore allows for 
the measurement of cellular DNA content and the determination of  cells distribution 
in the major cell-cycle phases (G1, S and G2/M) determined by peaks in a DNA content 
frequency histograms (Schönthal 2004).  
Analysis of the cell cycle distribution of NCI-H460 cells following treatment with the 
extract showed clear alterations in their cell cycle profile, which were however only 
considered to be statistically significant with the highest concentration (50 μg/mL) 
(Figure 12). Indeed, treatment with 50 μg/ml of extract resulted in an increase in the 
percentage of cells in G0/G1 phase from 52.6% (Blank cells) to 71.7% following the 
treatment (Figure 12). This was accompanied by a decrease in the % of cells in both the 
S and the G2/M phases of the cell cycle. Indeed, a decrease in the S phase from 29.1% 
(Blank) to 17.1% (following treatment) was observed, as well as a decrease in the 
G2/M phase from 18.1% (Blank) to 7.0% (following treatment).  
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Blank cells 
 
 
Control (H2O) 
 
 
25 μg/ml C. militaris  
 
 
 
 
50 μg/ml C. militaris  
 
 
 
 
 
Figure 12 - Effect of C. militaris methanolic extract in NCI-H460 cell cycle profile, analysed by 
flow cytometry. 
Cells, were treated for 48h with 25μg/ or 50μg/ml of C. militaris methanolic extract, with the 
corresponding volumes of solvent [H20 (1) and H2O (2), respectively and or medium only (Blank).  Panel 
A) Histograms of the cell cycle profile. Control corresponds to the highest volume of H2O. Images are 
representative of three independent experiments. Panel B) Cell cycle distribution. Results are the mean 
± SEM of 3 independent experiments. *P ≤ 0.05 between each treatment and the Blank.  
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This effect was similar to the one described in a previous study for C. militaris and its 
mycelial fermentation. In that study, both fractions caused an arrest in G0/G1 phase of 
GBM8401 (Human brain malignant glioma) cells. Nevertheless, the same extracts 
induced an arrest in the G2/M phase of U-87MG cells, suggesting that the effect 
caused by the extract can be dependent of the genetic background of the treated 
tumor cells (Yang et al. 2012). Of interest is also the fact that cordycepin [an isolated 
compound from Cordyceps genus, which seems to be present in the methanolic extract  
from C. militaris  (Liu et al. 2014)] induces cell cycle arrest in colorectal cancer cells at 
the G0/G1 phase (He et al. 2010). Although it is not known which compounds are 
responsible for the cell cycle arrest observed in the present study, the involvement of 
cordycepin in such activity is a possibility. Further studies, carried out in the cell line 
used in the present study could assess this hypothesis.  
 
4.1.4. Effect of C. militaris methanolic extract on NCI-H460 cellular 
apoptosis 
 
The decrease in cellular viability observed following treatment of NCI-H460 cells with 
the extract could also be due to increased apoptosis. This highly regulated energy-
dependent process is important for the maintenance of tissue homeostasis and 
elimination of damaged cells, which involves specific morphological and biochemical 
mechanisms (such as chromatin condensation, reduction in cell volume, endonuclease 
cleavage of DNA into oligonucleosomal length fragments (Koopman et al. 1994, Elmore 
2007, Park et al. 2009). 
In order to assess if the C. militaris methanolic extract induced apoptosis in the NCI-
H460 cell line, the levels of apoptosis were analyzed by flow cytometry following 
labeling with Annexin V-FITC/PI. This is a highly specific assay for apoptosis, based on 
the fact that during apoptosis some changes in the cell surface occur, namely the 
exposure of phosphatidylserine at the cell surface (being translocated from the inner 
side to the outer layer) as a result of the loss of membrane phospholipid asymmetry 
(Vermes et al. 1995). Therefore, the binding of Annexin-V-FITC to phosphatidylserine is 
used to detect apoptotic cells by flow cytometry (Koopman et al. 1994). In addition, 
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the combination of PI staining to the assay (which binds to nucleic acids only when the 
plasma membrane is compromised) allows for an indication of the cellular viability 
(Hawley and Hawley 2004, Riccardi and Nicoletti 2006).  
By analyzing the levels of apoptosis in NCI-H460 cells, 48 h following treatment with 
the extract, it was possible to observe a clear increase in cellular apoptosis in both the 
concentrations tested (Table 4). An increase in the levels of apoptosis from 7.4 % (in 
Blank cells) to 17.1 % and 26.7 % was observed in NCI-H460 cells treated with 25 
μg/mL or 50 μg/mL of the extract, respectively. These results showed that the extract 
was inducing apoptosis. As expected, and as previously observed in the other 
experiments carried out in this work, treatment with controls also had no effect on 
apoptosis. 
 
Table 4 - Apoptosis levels in NCI-H460 cells treated with C. militaris methanolic extract 
analyzed with Annexin V/PI staining by Flow Cytometry. 
 
  % Apoptosis 
Blank 7.4 % ± 0.6 % 
H20 8,5 % ± 2.3 % 
 
C. militaris 
25 µg/ml 17.1 % ± 1.6 % * 
50 µg/ml 26.4 % ± 5.3 % * 
Cells were treated for 48h with 25 μg/ml or 50 μg/ml) of the extract, with the highest volume of solvent 
or with medium only (Blank). Results are the mean ± SEM of 3 independent experiments. *P ≤ 0.05 
between each treatment and the Blank. 
 
To further confirm these results, the levels of PARP cleavage were analyzed by 
Western blot. PARP is an enzyme that is cleaved by proteases activated during 
apoptosis, being a useful hallmark of apoptosis (Gobeil et al. 2001). Results, from two 
experiments only, showed a decrease in total PARP levels, which might indicate that 
PARP is being cleaved (Figure 13). However, the corresponding band for cleaved PARP 
could not be observed. This may be due to possible technical problems associated with 
the antibody used. 
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 Blank H2O 25μg/ml 50μg/ml 
PARP 
 
Actin 
 
  
Figure 13 - Protein expression of PARP in NCI-H460 cells treated with the methanolic extract 
of C. militaris, analyzed by Western Blot. 
Cells were treated for 48h with 25 μg/ml or 50 μg/ml of the extract, with the highest volume of solvent 
or with medium only (Blank). Actin was used as loading control. Image is representative of 2 
independent experiments. 
 
 
Several studies have previously referred the apoptotic activity of other types of 
extracts from C. militaris. Indeed, different aqueous extracts from C. militaris (AECM) 
were shown to induce apoptosis in human leukemia cells (Park et al. 2005, Lee et al. 
2006), human breast cancer cells (Jin et al. 2008) and in human lung carcinoma cells 
(Park et al. 2009). In addition, some of the isolated compounds, namely Cordycepin, 
have shown activity as apoptosis inducers in several human tumor cells (Jeong et al. 
2011; Baik et al. 2012; Tuli et al. 2013). 
 
4.1.5. Effect of C. militaris methanolic extract on the cellular expression 
of p53 and p21  
 
Since the previous results showed that the extract reduced proliferation, altered cell 
cycle profile and increased apoptosis in NCI-H460 cells, the levels of p53 and p21 were 
analyzed by Western blot.   
Results showed an increase in the expression of p53 following cellular treatment with 
25 μg/ml or 50 μg/ml of the methanolic extract of C. militaris, when compared to Blank 
and Control cells. This was further confirmed by the increased expression of p53’s 
transcriptional target, p21 (Figure 14).  
p53, the guardian of the genome, is a tumor suppressor gene which is activated when 
cells are under stress or damaged (Efeyan and Serrano 2007). p53 activation causes 
C. militaris 
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blockage in cell cycle (and consequently in cellular proliferation) or may lead to 
apoptosis, thus allowing to prevent the development of the tumor (Amundson et al. 
1998, Vogelstein et al. 2000). One of the downstream targets of p53 is p21 protein, an 
inhibitor of cyclin-dependent kinases (CDKs, which are regulators of the cell cycle). p21 
inhibits CDKs and, consequently, inhibits the transition between G1 and S phases and 
between G2 and mitosis (Vogelstein et al. 2000). p53 is also known to induce apoptosis 
in damaged cells through activation of mitochondrial pro-apoptotic proteins from the 
Bcl-2 protein family, such as Bax, NOXA and P53AIP1 (Vogelstein et al. 2000). p53 is 
found mutated or inactivated in the majority of human cancers (Amundson et al. 1998, 
Vogelstein et al. 2000, Junttila and Evan 2009, Valente et al. 2013). Therefore, 
strategies aiming at the increase of p53’s activity are of extreme importance for cancer 
therapy. NCI-H460 cells, the cells line used in this study, have wild-type (wt) p53. 
Nevertheless, even wt p53 cancers may also have downstream members of the p53 
regulatory signalling pathway affected, which may lead to disruption in p53 functions 
(Athar et al. 2011).  p53 activation and of its targets may result in p53-dependent 
increase in cell death and cell cycle arrest, inhibiting the development of wt p53 
tumors. 
 
 Blank H2O 25μg/ml 50μg/m 
p53 
 
p21 
 
Actin 
 
Figure 14 – Expression levels of p53 and p21 expression in NCI-H460 cells following 
treatment with the methanolic extract of C. militaris, analyzed by Western Blot 
Cells were treated for 48h with 25 μg/ml or 50 μg/ml of the extract, with the highest volume of solvent 
or with medium only (Blank). Actin was used as loading control. Blot is representative of at least 3 
independent experiments (except for the image of p53 in the 25 μg/ml treatment, which is 
representative of 2 experiments only).  
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4.1.6. Effect of C. militaris methanolic extract on DNA damage 
 
Given that p53 activation may result from response to DNA damage (Amundson et al. 
1998), the expression of P-H2AX was also analyzed in cells treated with the extract. 
H2AX, a histone which is only present in eukaryotes, is phosphorylated (into P-H2AX) 
when single stranded breaks (SSBs) and particularly double stranded breaks (DSBs) 
occur. Being the key factor in damaged DNA repair, P-H2AX may be used as a 
biomarker for DNA damage (Kuo and Yang 2008). Results showed an increase in the 
levels of P- H2AX following the treatment with both concentrations of the methanolic 
extract of C. militaris (Figure 15 and data not shown), further supporting the 
hypothesis that the extract induced DNA damage which then lead to an increase in p53 
levels. 
 
 Blank H2O   50μg/ml 
P-H2Ax 
 
Actin 
 
Figure 15- Expression levels of P-H2AX in NCI-H460 cells following treatment with C. militaris 
methanolic extract, analyzed by Western blot. 
Cells were treated for 48 h with 50μg/ml of the extract, with the corresponding volume of solvent or 
with medium only (Blank).  Actin was used as loading control. Blot is representative of 2 independent 
experiments. 
 
To further confirm DNA damage induced by the extract, the cellular localization of 
53BP1 (p53-binding protein 1) was also analyzed by immunofluorescence. 53BP1 is a 
chromatin-associated factor described as being a DNA damage checkpoint mediator 
(DiTullio et al. 2002, Bartkova et al. 2007, Fradet-Turcotte et al. 2013). Following DNA 
damage, 53BP1 co-localizes with DNA damage response proteins, such as P-H2AX, 
playing a role early in the DNA damage response pathway (Ward et al. 2003, Kuo and 
Yang 2008). In addition, 53BP1 has also been proposed as a transcriptional co-activator 
of the p53 tumor suppressor (Schultz et al. 2000, DiTullio et al. 2002).  
Results showed an increase in the number of small foci following treatment with both 
concentrations of C. militaris methanolic extract (Figure 16). 
C. militaris 
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Blank 
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Figure 16- Effect of C. militaris methanolic extract in the levels of 53BP1 small foci in NCI-
H460, analysed by immunoflourescence assay. 
Cells were treated for 48h with 25μg/ml or 50μg/ml of the extract, with the highest volume of solvent or 
with medium only (Blank). Panel A) Fluorescence microscopy images of 53BP1 staining in green (from 
FITC) and cell nuclei in blue (from DAPI). Panel B) Quantification of the number of 53BP-1 small foci. 
Results are represented as the mean ± SEM of 3 independent experiments. Iamges are representative of 
three independent experiments. Bar corresponds to 20 μm. 
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Results - Part II 
4.2. Effect of extracts from Suillus luteus and Morchella 
esculenta in THP-1 cell line 
 
Modulation of the immune system and consequently of immune responses, aiming at 
helping the fight against diseases (such as cancer) has been of interest for the scientific 
and medical community (Sharififar et al. 2009). 
This part of the project, aimed at studying the immunomodulatory effect of two 
mushrooms extracts (a polysacharidic extract from S. luteus and a phenolic extract 
from M. esculenta) in THP-1 cell line. This cell line is a suspension cell type which 
resembles circulating primary monocytes. When THP-1 cells are exposed to PMA, 
mitosis is stopped and monocytes adhere to the culture plate and differentiate into 
mature macrophages (Kang et al. 2014). Thus, this THP-1 cell line allows us to study the 
effect of mushroom extracts not only in monocytes but also in differentiated 
macrophages. 
The work started by evaluating the effect of both extracts in the THP-1 cellular viability 
in order to exclude their possible cytotoxicity. This was carried out both in THP-1 
monocytes as well as in THP-1 differentiated macrophages. 
For this, two different assays were selected: i) MTS assay in the case of THP-1 
monocytes and ii) Sulforhodamine B assay in the case of THP-1 macrophages.  Since 
there is not much information in the literature about these methodologies when 
applied to this particular cell line, preliminary studies were carried out to optimize the 
corresponding protocols. The optimization procedure, as well as the preliminary 
results from the analysis of the cytotoxic effect of the extracts will be presented and 
discussed below.  
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4.2.1. Effect of a PLS extract from S. luteus and phenolic extract from M. 
esculenta in THP-1 monocytes 
 
The MTS assay, a colorimetric assay that measures metabolic activity, was chosen to 
assess the effect of the extracts in THP-1 cells. This assay measures the production of 
aqueous soluble formazan following conversion of a tetrazolium salt by mitochondrial 
activity of viable cells at 37oC. This coloured aqueous soluble formazan, produced by 
dehydrogenase enzymes, allows to indirectly determinate cell number, since the 
amount of formazan formed is directly proportional to the number of viable cells. 
When cells die, they lose the ability to convert MTS into formazan, thus color 
formation serves as a useful and convenient marker of viable cells only (Malich et al. 
1997). The MTS is an alternative assay to the well known MTT assay, another 
colorimetric assay for assessing cell viability, with the advantage that the formazan 
formed from MTS is water soluble and less toxic when compared to the compound 
formed in the MTT assay (Wang et al. 2010). 
The protocol for MTS assay applied to the THP1 cell line required optimization, in 
particular regarding the duration of incubation with MTS (prior to determination of 
absorbance), and the number of cells plated at the beginning of the assay. Therefore, 
in order to optimize the MTS protocol, increasing number of THP-1 cells were plated in 
different wells from a 96 well-plate and incubated for 48 h. After this period, the MTS 
solution was added to each well and the absorbance was measured at 1 h intervals, up 
to 4 h. Analysis of the results of formazan detection during the 4 h period of incubation 
with MTS, allowed to observe an increase in absorbance with the incubation period, 
with the maximum absorbance being measured at 3 h (Figure 17). No further increase 
in the absorbance was observed at 4 h. Therefore, the 3 h incubation period with MTS 
was chosen to analyse the results. When observing the absorbance obtained for the 
different number of cells plated, no differences were observed for the lowest range of 
cell number (below 2.500 cells/well).  Indeed, clear differences were only observed in 
wells in which more than  5.000 cells were plated, increasing proportionally to the 
highest cell number analysed (12.500 cells/well) (Figure 17). 
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Figure 17 - MTS Preliminary assay 
Cells were plated for 48 h. Absorvance was measured after MTS incubation for 4 h (at 1 h intervals). 
Results are from one experiment only. 
 
 
Based on the results from this preliminary experiment, it was decided to carry out 
further experiments by plating cells at 10.000 cells/well for 48 h and by analysing 
absorbance following 3 h incubation with MTS.  
In order to test the effect of the extracts in THP-1 monocytes, cells were treated for 48 
h with five serial dilutions of each extract (PLS extract from S. luteus and phenolic 
extract from M. esculenta; both ranging from 25 μg/mL to 400 μg/mL).  
Interestingly, results from the MTS assay showed a dose-dependent increase in 
metabolic activity of cells treated with PLS extract from S. luteus (Figure 18-panel A). 
Indeed, an increase to 150% and 180% was observed with the two highest 
concentrations of extract (200 μg/mL and 400 μg/mL, respectively). These results 
indicate that S. Luteus PLS extract not only is not toxic to THP-1 cells but also, and 
importantly, it seems to stimulate their proliferation, as suggested by the increase in 
MTS activity. When analysing the results following treatment with M. esculenta 
phenolic extract, no significant effect in metabolic activity of THP-1 cells was observed 
(Figure 18-panel B), which suggests that this extract is not cytotoxic to this cell line. 
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As expected, H2O (the extracts solvent) had no effect in cellular metabolic activity, and 
presented no toxicity to the cells. 
 
Figure 18 - Effect of the extracts in the metabolic activity of THP-1 monocytes, analysed by 
MTS assay. 
Cells were treated for 48h with S. luteus PLS extract (panel A) and with M. esculenta phenolic extract 
(panel B). Absorbance was analyzed as percentage in relation to blank cells. Results are the mean ± SEM 
of 3 independent experiments. *P ≤ 0.05 between each treatment and the blank 
 
Previous studies have shown that different extracts of S. luteus were not toxic to a 
non-tumor cell line model, namely primary cultures of porcine hepatocytes, at least in 
same range of concentrations as the ones tested in the present study (Santos et al. 
2013). Although, there is no information regarding the cytotoxicity of M. Esculenta. 
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In addition to the evaluation of the effect of the extracts on THP-1 cellular viability 
(analysed with MTS assay) cells were carefully monitored in order to assess the 
possibility that the extracts induce their differentiation into macrophages.  However, 
no alterations in the cellular morphology nor in the adhesion of the cells to the culture 
plates were observed during this period, indicating that neither of the extracts induce 
differentiation of the THP-1 cells. 
 
4.2.2. Effect of PLS extract from S. luteus and phenolic extract from M. 
esculenta in THP-1 differentiated macrophages  
 
To evaluate the effect of the same extracts in THP-1 differentiated macrophages 
(following treatment with PMA), the colorimetric SRB assay was carried out. SRB binds 
stoichiometrically to basic amino-acid residues under mild acidic conditions, and 
dissociates under basic conditions, thus allowing to indirectly determining cell density. 
(Vichai and Kirtikara 2006). 
To optimize the SRB assay protocol for THP-1 differentiated macrophages, increasing 
number of cells were plated in 96 well plates, and treated with PMA for 18 h at 37 ⁰C 
to induce differentiation. After this period, cells were observed under an inverted optic 
microscope (Nikon Eclipse TS100) to confirm that cell differentiation (from monocytes 
to macrophages) had occurred. As previously referred (in the 4.2 section), this may be 
evaluated by the ability of adhesion gained by cells, following treatment with PMA. In 
fact, the cells observed had a more elongated, flat and amoeboid shape, suggesting 
that they had attached to the bottom of the plate. After confirming differentiation, cell 
culture medium was replaced with fresh medium (without PMA) and cells incubated 
for 24 h to induce maturation. After this period, fresh medium was added to cells 
which were further incubated for 48 h and then analysed with the SRB assay. The SRB 
assay was also carried out in the T0 plate (corresponding to the cells fixed at time zero 
- time at which the extracts were added) in order to assess cell growth following 
differentiation. 
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As expected, no differences were observed between cells in the T0 plate and cells 
following further 48 h in culture (Figure 19). This was already expected since it its 
known that differentiated cells do not proliferate (Qin 2012).  
 
Figure 19 - SRB Preliminary assay 
THP-1 differentiated macrophages were incubated for 48 h with medium. SRB assay was carried out at 0 
h ()T0 and 48h (T48). Results are from one experiment only. 
 
 
 
 
In addition, when analysing absorbance measured from the different number of cells 
plated, no differences were observed for the lowest number of cells plated (below 
12.500 cells/well). Indeed, differences were only observed with more than 25.000 
cells/well, increasing proportionally to the highest cell number analysed, 200.000 
cells/well (Figure 19). Based on the results from this preliminary experiment, the 
following experiments were carried out starting with 50.000 cells/well. 
To test the effect of the extracts in THP-1 differentiated macrophages, cells were 
treated for 48 h (after a period of  differentiation and maturation as explained above) 
with five serial dilutions of each extract (PLS extract from S. luteus and Phenolic extract 
from M. esculenta; ranging from 25 μg/mL to 400 μg/mL).  
Results from the SRB assay allowed to observe that both extracts, S. luteus PLS extract 
(Figure 20-panel A) and M. esculenta phenolic extract (Figure 20-panel B), had no 
significant effect in cell growth of THP-1 differentiated macrophages. This suggests 
that none of the extracts presented cytotoxicity to these cells. As previously 
mentioned, this had also been observed for THP-1 monocytes. Interestingly, the 
increased metabolic activity observed in THP-1 monocytes following treatment with S. 
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luteus PLS extract was not observed in the THP-1 differentiated cells. This may be 
explained by the fact that THP-1 monocytes correspond to an immature cell line, 
probably with more proliferation potential than the differentiated macrophages (a 
mature cell).  
 
Figure 20 - Effect of the extracts in THP-1 differentiated macrophages, analysed by SRB 
assay. 
THP-1 differentiated macrophages were treated for 48h with S. luteus PLS extract (panel A) or with M. 
esculenta phenolic extract (panel B). Absorbance was analyzed as percentage in relation to blank cells. 
Results are the mean ± SEM from 4 independent experiments.  
 
 
Although the initial aim of this part of the work was to study the immunomodulatory 
effect of the referred extracts, it was not possible to completely achieve this goal, due 
to time constrains. Based on these results, future work will be carried out namely the 
immunomodulatory activity of Suillus luteus (polysachararidic (PLS) extract), Morchella 
esculenta (phenolic extract) and also other extracts from Suillus luteus and Morchella 
esculenta using the THP-1 cell line.  
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Mushrooms have been recognized not only for their nutritional but also for their 
medicinal properties. Indeed, a great interest has been given to exploring different 
bioactive compounds or extracts, which may have different properties. Despite the 
fact that there is intensive research on the therapeutic potential of several 
mushrooms, many of them, as well as their specific mechanisms of action, remain 
unknown (Rathee et al. 2012).  
Therefore, this work aimed at further gaining insight into the antitumoral and 
immunomodulatory activity of different extracts from edible mushrooms. 
In the first part of the study, the mechanism of action of a methanolic extract of 
Cordyceps militaris (which was previously shown to inhibitory the growth of human 
tumor cells) was investigated using NCI-H460 cells as a model. Results clearly showed 
that this extract decreased NCI-H460 viable cell number, causing a strong reduction in 
cellular proliferation, a cell cycle arrest in the G0/G1 phase and an increase in 
apoptosis. Moreover, treatment with this extract was shown to increase the 
expression levels of p53 and its transcriptional target p21, probably by the induction of 
DNA damage. Indeed, an increase in both the expression of P-H2AX and in the number 
of 53BP1 foci (both markers of DNA damage) were observed after treatment with this 
extract.  
Although a few studies had already been carried out in human tumor cell lines using 
this extract, this was the first study in which its mechanism of action was associated to 
an increase in p53 expression. Since p53 is an important therapeutic target, due to fact 
that its activation may result in cell cycle delay and induction of apoptosis, extracts 
with proven ability to increase its expression may be of added value to the 
development of anticancer therapies. However, further studies would be needed in 
order to further explore this potential. In fact, it would be interesting to confirm if the 
same effect (observed in NCI-H460 cells) would be observed after silencing p53 
expression (transiently with siRNAs or stably with shRNAs) in this cell line. One other 
approach to verify if the effects observed were p53-dependent would be to study the 
mechanism of action in other tumor cell lines which have different p53 status. Other 
studies suggest other possible therapeutic mechanisms caused by the C. militaris 
extracts and their compounds, e.g. associated with autophagy (Yang et al. 2012). It 
would be interesting to confirm this in future work. Also important would be to assess 
the specificity of this extract towards tumor cells, by testing this extract in non-tumor 
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cells and evaluating their possible toxicity. Regarding this, the study in which this work 
was based (Reis et al. 2013) had already described that this extract showed no effect in 
the cell growth of primary cells of porcine liver (PLP2). Nevertheless, it would be 
interesting to use human cell lines to address this issue. In addition, the effect of the 
extract could be also analysed in animal models (namely in models of human tumor 
cell lines xenografted in nude mice) to confirm its activity in vivo. Furthermore, it is not 
known if the observed effect is due to any particular compound included in the extract 
or the mixture of several compounds. The isolation and analysis of the effect of the 
different compounds present in this extract (including cordycepin) would be 
interesting to identify the bioactive compound(s) that is (are) responsible for the 
observed biological effects. Nevertheless, it is also possible that the whole extract 
presents an effect that is not reproducible by treatment with the isolated compounds.   
In the second part of the study, an evaluation of the immunomodulatory potential of 
two different extracts, S. Luteus PLS and M. esculenta phenolic extract, was carried out 
in THP-1 cells.  Although due to time constrains it was not possible to fully conclude 
this study, the work carried out allowed to analyse the effect of both extracts in the 
viability of THP-1 cell lines (both in monocytes as well as in macrophages). None of the 
extracts was found to be toxic towards THP-1 cells (monocytes and macrophages), at 
least in the range of concentrations analysed. Interestingly, an increase in THP-1 
monocytes metabolic activity, suggestive of increased proliferation was observed after 
treatment.  In addition, it was also possible to conclude that neither of extracts (at 
least in the range of concentrations analysed) induced differentiation of THP-1 
monocytes into macrophages. Based on the information gathered, future studies 
specifically aiming at assessing the immunomodulatory activity of these compounds 
will be carried out by the research group. This may include analysis of the levels of 
mRNA and/or protein of NF-κB, pro-inflammatory cytokines (e.g. IL-1b and TNF-α) and 
inflammation-related enzymes (e.g. COX-2). If the immunomodulatory activity is 
proven, this may support the possible use of these extracts as an adjuvant to 
anticancer therapy.  
Overall, the work carried out in this thesis further supports the potential of 
mushrooms extracts in the search for bioactive compounds. 
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Mushroom extracts have been studied extensively for their potential antitumor effect in 
tumor cell lines and in animal models [1]. Recently, some of our collaborators have 
described that the methanolic extract from the medicinal mushroom Cordyceps militaris  
(L.) Link presented tumor cell growth inhibitory activity. In particular, this extract 
inhibited the growth of the non-small cell lung cancer (NSCLC) cell line NCI-H460, 
presenting a GI50 of approximately 50 µg/ml [2].  
The aim of this work was to further study the effect of C. militaris methanolic extract in 
NCI-H460 cells, regarding its mechanism of action. 
NCI-H460 cells were treated with C. militaris methanolic extract (at 25 and 50 µg/ml) 
for 48 h. Viable cell number was then assessed with the Trypan blue exclusion assay. 
Cellular proliferation was analyzed with the BrdU incorporation assay and cell cycle 
profile with flow cytometry following propidium iodide (PI) labeling. Levels of 
apoptotic cell death were determined with flow cytometry following Annexin V-FITC 
/PI labeling. 
Treatment of cells with the C. militaris extract caused a dose-dependent decrease in 
viable cell number. Moreover, a clear and strong decrease in cellular proliferation was 
observed. In addition, alterations in cell cycle profile were found, with a strong decrease 
in the S and G2/M phases of the cell cycle together with an increase in G0/G1 phase. 
Furthermore, treatment with the extract also induced apoptosis in this cell line. 
In conclusion, C. militaris methanolic extract was shown to interfere with cell 
proliferation, cell cycle and to induce apoptosis of NCI-H460 cells. Further studies will 
aim at further understanding the mechanism of action of this extract. 
 
References: 
[1] Ferreira, I.C., J.A. Vaz, M.H. Vasconcelos, and A. Martins. (2010), Compounds from wild 
mushrooms with antitumor potential. Anti-cancer agents in medicinal chemistry. 10:424-436 
[2] Reis, F.S., Barros, L., Calhelha, R.C., Cirić, A., van Griensven, L.J., Soković, M., Ferreira, 
I.C. (2013), The methanolic extract of Cordyceps militaris (L.) Link fruiting body shows 
antioxidant, antibacterial, antifungal and antihuman tumor cell lines properties, Food and 
chemical toxicology, 62:91-98.         
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Background
Mushroom extracts have been studied extensively for their potential
antitumor effect in tumor cell lines and in animal models [1]. Recently,
some of our collaborators have described that the methanolic extract
from the medicinal mushroom Cordyceps militaris (L.) Link presented
tumor cell growth inhibitory activity. In particular, this extract inhibited
the growth of the non-small cell lung cancer (NSCLC) cell line NCI-H460,
presenting a GI50 of approximately 50 μg/ml [2].
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To further study the effect of C. militaris methanolic extract in NCI-H460
cells, regarding its mechanism of action.
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Results
Conclusion
C. militaris methanolic extract was shown to interfere with cellular proliferation, cell cycle profile and to induce apoptosis of NCI-H460 cells. Further 
studies will aim at further understanding the mechanism of action of this extract.
References
[1] Ferreira et al. Anti-cancer agents in medicinal chemistry.2010; 10:424-436 [2] Reis et al. Food and chemical toxicology, 2013; 62:91-98.
7º Encontro Investigação Jovem da Universidade do Porto
Porto, February, 12-14, 2014
% Apoptosis
Blank 6.3% ± 1,4%
H20 (1) 5,8% ± 1.6%
H20 (2) 7.1% ± 2,1%
C. militaris
25 µg/ml 14.2% ± 3,1%
50 µg/ml 23.0% ± 5,2%
Figure 2. Analysis of the effect of C. militaris methanolic extract in NCI-H460 cell cycle profile by
flow cytometry. Results are the mean ± SE of 3 independent experiments. * P ≤ 0,05 between
each treatment and the Black.
Figure 1. Analysis of the effect of C. militaris methanolic extract in NCI-H460 viable cell
number with Trypan Blue exclusion assay. Cells were treated for 48 h with 25 µg/ml
(corresponding to the ½ Gi50 concentration) and 50 µg/ml (corresponding to the Gi50
concentration) of C. militaris methanolic extract, with the corresponding volumes of solvent
[H20 (1) and H2O (2), respectively]. Results are presented as a percentage of viable cells in
relation to blank cells (treated with medium only) and are shown as mean ± SE of 3
independent experiments. * P ≤ 0,05 between each treatment and the Blank.
 C. militaris methanolic extract decreased NCI-H460 cells viability
 C. militaris methanolic extract affected the NCI-H460 normal cell cycle profile:
• Decrease in S and G2/M phases
• Increase in G0/G1 phase
Results are presented as a percentage of apoptotic cells and are shown as mean ±SE of 4
independent experiments. * P ≤ 0,05 between each treatment and the Blank.
 C. militaris methanolic extract induced apoptosis in NCI-H460 cells
Table 1. Percentage of apoptotic cells, analysed with Annexin V/PI staining by Flow Cytometry
Effect of C. militaris methanolic extract on NCI-H460 viable cell number
Effect of C. militaris methanolic extract on NCI-H460 cell cycle profile
Effect of C. militaris methanolic extract on NCI-H460 cellular apoptosis
Effect of C. militaris methanolic extract on NCI-H460 cellular proliferation
Figure 3. Analysis of the effect C. militaris methanolic extract in NCI-H460 cellular
proliferation by the BrdU incorporation assay. Results are presented as a percentage of
cellular proliferation and are shown as mean ±SE of 3 independent experiments (except for the
case of 25 µg/ml in which the results are the mean of 2 experiments only). * P ≤ 0,05 between
each treatment and the Blank.
 C. militaris methanolic extract decreased NCI-H460 cellular proliferation
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Experimental Design
NCI-H460 cells
Non- small cell lung cancer
C. militaris
methanolic extract
48H
Viable cell number
Trypan blue exclusion assay
Cell cycle profile 
PI staining (Flow Cytometry)
Cell death by Apoptosis 
Annexin V/PI staining (Flow cytometry)
Cellular proliferation
BrdU Incorporation Assay
Expression of proteins involved in cell cycle
Western Blot
Figure 4. Expression of p53 and p21 in NCI-H460 cells following treatment with 50µg/ml C.
militaris, analysed by Western blot. Actin was used as loading control. Blot is representative of
2 or 3 independent experiments (for p21 and p53 respectively).
Effect of C. militaris methanolic extract on  the cellular expression of 
p53 and p21
 C. militaris methanolic treatment increased the expression of p53 and p21
in NCI-H460 cells
Blank H20 50μg/ml
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